Patent Grant
7732446
The invention relates to compounds that may be used to inhibit dipeptidyl peptidases as well as compositions of matter and kits comprising these compounds. The present invention also relates to methods for inhibiting dipeptidyl peptidases as well as treatment methods using compounds according to the present invention.
Dipeptidyl Peptidase IV (IUBMB Enzyme Nomenclature EC.3.4.14.5) is a type II membrane protein that has been referred to in the literature by a wide a variety of names including DPP4; DP4; DAP-IV; FAPβ adenosine deaminase complexing protein 2; adenosine deaminase binding protein (ADAbp); dipeptidyl aminopeptidase IV; Xaa-Pro-dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase IV; lymphocyte antigen CD26; glycoprotein GP110; dipeptidyl peptidase IV; glycylproline aminopeptidase; glycylproline aminopeptidase; X-prolyl dipeptidyl aminopeptidase; pep X; leukocyte antigen CD26; glycylprolyl dipeptidylaminopeptidase; dipeptidyl-peptide hydrolase; glycylprolyl aminopeptidase; dipeptidyl-aminopeptidase IV; DPP IV/CD26; amino acyl-prolyl dipeptidyl aminopeptidase; T cell triggering molecule Tp103; and X-PDAP. Dipeptidyl Peptidase IV is referred to herein as “DPP-IV”.
DPP-IV is a non-classical serine aminodipeptidase that removes Xaa-Pro dipeptides from the amino terminus (N-terminus) of polypeptides and proteins. DPP-IV dependent slow release of dipeptides of the type X-Gly or X-Ser has also been reported for some naturally occurring peptides.
DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. DPP-IV has been implicated in a number of disease states, some of which are discussed below.
DPP-IV is responsible for the metabolic cleavage of certain endogenous peptides (GLP-1 (7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro.
GLP-1 (7-36) is a 29 amino-acid peptide derived by post-translational processing of proglucagon in the small intestine. GLP-1 (7-36) has multiple actions in vivo including the stimulation of insulin secretion, inhibition of glucagon secretion, the promotion of satiety, and the slowing of gastric emptying. Based on its physiological profile, the actions of GLP-1 (7-36) are believed to be beneficial in the prevention and treatment of type II diabetes and potentially obesity. For example, exogenous administration of GLP-1 (7-36) (continuous infusion) in diabetic patients has been found to be efficacious in this patient population. Unfortunately, GLP-1 (7-36) is degraded rapidly in vivo and has been shown to have a short half-life in vivo (t1/2=1.5 minutes).
Based on a study of genetically bred DPP-IV knock out mice and on in vivo/in vitro studies with selective DPP-IV inhibitors, DPP-IV has been shown to be the primary degrading enzyme of GLP-1 (7-36) in vivo. GLP-1 (7-36) is degraded by DPP-IV efficiently to GLP-1 (9-36), which has been speculated to act as a physiological antagonist to GLP-1 (7-36). Inhibiting DPP-IV in vivo is therefore believed to be useful for potentiating endogenous levels of GLP-1 (7-36) and attenuating the formation of its antagonist GLP-1 (9-36). Thus, DPP-IV inhibitors are believed to be useful agents for the prevention, delay of progression, and/or treatment of conditions mediated by DPP-IV, in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
DPP-IV expression is increased in T-cells upon mitogenic or antigenic stimulation (Mattem, T., et al., Scand. J. Immunol., 1991, 33, 737). It has been reported that inhibitors of DPP-IV and antibodies to DPP-IV suppress the proliferation of mitogen-stimulated and antigen-stimulated T-cells in a dose-dependant manner (Schon, E., et al., Biol. Chem., 1991, 372, 305). Various other functions of T-lymphocytes such as cytokine production, IL-2 mediated cell proliferation and B-cell helper activity have been shown to be dependent on DPP-IV activity (Schon, E., et al., Scand. J. Immunol., 1989, 29, 127). DPP-IV inhibitors, based on boroProline, (Flentke, G. R., et al., Proc. Nat. Acad. Sci. USA, 1991, 88, 1556) although unstable, were effective at inhibiting antigen-induced lymphocyte proliferation and IL-2 production in murine CD4+ T-helper cells. Such boronic acid inhibitors have been shown to have an effect in vivo in mice causing suppression of antibody production induced by immune challenge (Kubota, T. et al., Clin. Exp. Immun., 1992, 89, 192). The role of DPP-IV in regulating T lymphocyte activation may also be attributed, in part, to its cell-surface association with the transmembrane phosphatase, CD45. DPP-IV inhibitors or non-active site ligands may possibly disrupt the CD45-DPP-IV association. CD45 is known to be an integral component of the T-cell signaling apparatus. It has been reported that DPP-IV is essential for the penetration and infectivity of HIV-1 and HIV-2 viruses in CD4+ T-cells (Wakselman, M., Nguyen, C., Mazaleyrat, J.-P., Callebaut, C., Krust, B., Hovanessian, A. G., Inhibition of HIV-1 infection of CD 26+ but not CD 26-cells by a potent cyclopeptidic inhibitor of the DPP-IV activity of CD 26. Abstract P.44 of the 24th European Peptide Symposium 1996). Additionally, DPP-IV has been shown to associate with the enzyme adenosine deaminase (ADA) on the surface of T-cells (Kameoka, J., et al., Science, 193, 26 466). ADA deficiency causes severe combined immunodeficiency disease (SCID) in humans. This ADA-CD26 interaction may provide clues to the pathophysiology of SCID. It follows that inhibitors of DPP-IV may be useful immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
It has been shown that lung endothelial cell DPP-IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells (Johnson, R. C., et al., J. Cell. Biol., 1993, 121, 1423). DPP-IV is known to bind to fibronectin and some metastatic tumor cells are known to carry large amounts of fibronectin on their surface. Potent DPP-IV inhibitors may be useful as drugs to prevent metastases of, for example, breast and prostrate tumors to the lungs.
High levels of DPP-IV expression have also been found in human skin fibroblast cells from patients with psoriasis, rheumatoid arthritis (RA) and lichen planus (Raynaud, F., et al., J. Cell. Physiol., 1992, 151, 378). Therefore, DPP-IV inhibitors may be useful as agents to treat dermatological diseases such as psoriasis and lichen planus.
High DPP-IV activity has been found in tissue homogenates from patients with benign prostate hypertrophy and in prostatosomes. These are prostate derived organelles important for the enhancement of sperm forward motility (Vanhoof, G., et al., Eur. J. Clin. Chem. Clin. Biochem., 1992, 30, 333). DPP-IV inhibitors may also act to suppress sperm motility and therefore act as a male contraceptive agent. Conversely, DPP-IV inhibitors have been implicated as novel agents for treatment of infertility, and particularly human female infertility due to Polycystic ovary syndrome (PCOS, Stein-Leventhal syndrome) which is a condition characterized by thickening of the ovarian capsule and formation of multiple follicular cysts. It results in infertility and amenorrhea.
DPP-IV is thought to play a role in the cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides.
Stimulated hematopoietic cells are useful for the treatment of disorders that are characterized by a reduced number of hematopoietic cells or their precursors in vivo. Such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer. It was discovered that inhibitors of dipeptidyl peptidase type IV are useful for stimulating the growth and differentiation of hematopoietic cells in the absence of exogenously added cytokines or other growth factors or stromal cells. This discovery contradicts the dogma in the field of hematopoietic cell stimulation, which provides that the addition of cytokines or cells that produce cytokines (stromal cells) is an essential element for maintaining and stimulating the growth and differentiation of hematopoietic cells in culture. (See, e.g., PCT Intl. Application No. PCT/US93/017173 published as WO 94/03055).
DPP-IV in human plasma has been shown to cleave N-terminal Tyr-Ala from growth hormone-releasing factor and cause inactivation of this hormone. Therefore, inhibitors of DPP-IV may be useful in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth.
DPP-IV can also cleave neuropeptides and has been shown to modulate the activity of neuroactive peptides substance P, neuropeptide Y and CLIP (Mentlein, R., Dahms, P., Grandt, D., Kruger, R., Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 1993; Wetzel, W., Wagner, T., Vogel, D., Demuth, H.-U., Balschun, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes, Neuropeptides, 31, 41, 1997). Thus DPP-IV inhibitors may also be useful agents for the regulation or normalization of neurological disorders.
Several compounds have been shown to inhibit DPP-IV. Nonetheless, a need still exists for new DPP-IV inhibitors that have advantageous potency, stability, selectivity, toxicity and/or pharmacodynamics properties. In this regard, a novel class of DPP-IV inhibitors are provided herein.
The present invention relates to compounds that have activity for inhibiting DPP-IV. It is noted that these compounds may also have activity for inhibiting other S9 proteases and thus may be used against these other S9 proteases as well as DPP-IV. The present invention also provides compositions, articles of manufacture and kits comprising these compounds.
In one embodiment, a pharmaceutical composition is provided that comprises a DPP-IV inhibitor according to the present invention as an active ingredient. Pharmaceutical compositions according to the invention may optionally comprise 0.001%-100% of one or more DPP-IV inhibitors of this invention. These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compositions may also be administered or coadministered in slow release dosage forms.
The invention is also directed to kits and other articles of manufacture for treating disease states associated with DPP-IV.
In one embodiment, a kit is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.
In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The article of manufacture may also optionally comprise additional components, such as syringes for administration of the composition. The article of manufacture may comprise the composition in single or multiple dose forms.
Also provided are methods for preparing compounds, compositions and kits according to the present invention. For example, several synthetic schemes are provided herein for synthesizing compounds according to the present invention.
Also provided are methods for using compounds, compositions, kits and articles of manufacture according to the present invention.
In one embodiment, the compounds, compositions, kits and articles of manufacture are used to inhibit DPP-IV.
In another embodiment, the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state.
In another embodiment, a compound is administered to a subject wherein DPP-IV activity within the subject is altered, preferably reduced.
In another embodiment, a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits DPP-IV.
In another embodiment, a method of inhibiting DPP-IV is provided that comprises contacting DPP-IV with a compound according to the present invention.
In another embodiment, a method of inhibiting DPP-IV is provided that comprises causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
In another embodiment, a method of inhibiting DPP-IV is provided that comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo. It is noted that the compounds of the present invention may be the first or second compounds.
In another embodiment, a therapeutic method is provided that comprises administering a compound according to the present invention.
In another embodiment, a method of inhibiting cell proliferation is provided that comprises contacting a cell with an effective amount of a compound according to the present invention.
In another embodiment, a method of inhibiting cell proliferation in a patient is provided that comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
In another embodiment, a method of treating a condition in a patient which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors, is provided that comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
In another embodiment, a method is provided for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of a disease state which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors.
In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.
In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state. It is noted that the compounds of the present invention may be the first or second compounds.
In another embodiment, a method is provided for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.
In another embodiment, a method is provided for treating a cell proliferative disease state comprising treating cells with a compound according to the present invention in combination with an anti-proliferative agent, wherein the cells are treated with the compound according to the present invention before, at the same time, and/or after the cells are treated with the anti-proliferative agent, referred to herein as combination therapy. It is noted that treatment of one agent before another is referred to herein as sequential therapy, even if the agents are also administered together. It is noted that combination therapy is intended to cover when agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time.
Examples of diseases that may be treated by administration of compounds and compositions according to the present invention include, but are not limited to conditions mediated by DPP-IV, in particular diabetes, more particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation, obesity, immunosuppressants or cytokine release regulation, autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis, AIDS, cancers (prevention of metastases, for example, breast and prostrate tumors to the lungs), dermatological diseases such as psoriasis and lichen planus, treatment of female infertility, osteoporosis, male contraception and neurological disorders.
It is noted in regard to all of the above embodiments that the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well known in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers. Further, unless otherwise specified, recitation of a compound is intended to encompass all possible resonance forms and tautomers. With regard to the claims, the language “compound comprising the formula” is intended to encompass the compound and all pharmaceutically acceptable ionized forms and solvates, all possible stereoisomers, and all possible resonance forms and tautomers unless otherwise specifically specified in the particular claim.
It is further noted that prodrugs may also be administered which are altered in vivo and become a compound according to the present invention. The various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention. It is also noted that certain compounds of the present invention may be altered in vivo prior to inhibiting DPP-IV and thus may themselves be prodrugs for another compound. Such prodrugs of another compound may or may not themselves independently have DPP-IV inhibitory activity.
Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this Application.
“Alicyclic” means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized. Examples of alicyclic moieties include, but are not limited to moieties with C3-8 rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.
“Aliphatic” means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.
“Alkoxy” means an oxygen moiety having a further alkyl substituent. The alkoxy groups of the present invention can be optionally substituted.
“Alkyl” represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See “oxaalkyl”) or nitrogen atoms (See “aminoalkyl”) between the carbon atoms. CX alkyl and CX-Y alkyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl represented along with another radical (e.g., as in arylalkyl, heteroarylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C6-10)aryl(C1-3)alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).
“Alkylene”, unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical. CX alkylene and CX-Y alkylene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkylene includes methylene (—CH2—), ethylene (—CH2CH2—), trimethylene (—CH2CH2CH2—), tetramethylene (—CH2CH2CH2CH2—) 2-butenylene (—CH2CH═CHCH2—), 2-methyltetramethylene (—CH2CH(CH3)CH2CH2—), pentamethylene (—CH2CH2CH2CH2CH2—) and the like).
“Alkylidene” means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond. CX alkylidene and CX-Y alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C1-6 alkylidene includes methylene (═CH2), ethylidene (═CHCH3), isopropylidene (═C(CH3)2), propylidene (═CHCH2CH3), allylidene (═CH—CH═CH2), and the like).
“Amino” means a nitrogen moiety having two further substituents where, for example, a hydrogen or carbon atom is attached to the nitrogen. For example, representative amino groups include —NH2, —NHCH3, —N(CH3)2, —NHC1-3-alkyl, —N(C1-3-alkyl)2, —NHC3-10-aryl and the like. Optionally, the two substituents together with the nitrogen may also form a ring. Unless indicated otherwise, the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
“Aminoalkyl” means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (—N—) are positioned between carbon atoms of the alkyl. For example, an (C2-6) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
“Animal” includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
“Aromatic” means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp2 hybridized and the total number of pi electrons is equal to 4n+2. An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).
“Aryl” means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. CX aryl and CX-Y aryl are typically used where X and Y indicate the number of atoms in the ring.
“Bicycloalkyl” means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.
“Bicycloaryl” means a bicyclic ring assembly wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic. CX bicycloaryl and CX-Y bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring.
“Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other. Non-exclusive examples of common compounds having a bridging ring include borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like. One or both rings of the bicyclic system may also comprise heteroatoms.
“Carbamoyl” means the radical —OC(O)NRaRb where Ra and Rb are each independently two further substituents where a hydrogen or carbon atom is attached to the nitrogen.
“Carbocycle” means a ring consisting of carbon atoms.
“Carbocyclic ketone derivative” means a carbocyclic derivative wherein the ring contains a —CO— moiety.
“Carbonyl” means the radical —CO—. It is noted that the carbonyl radical may be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.
“Carboxy” means the radical —CO2—. It is noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.
“Cyano” means the radical —CN.
“Cycloalkyl” means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly. CX cycloalkyl and CX-Y cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly. For example, C3-10 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, and the like.
“Cycloalkylene” means a divalent saturated or partially unsaturated, monocyclic or polycyclic ring assembly. CX cycloalkylene and CX-Y cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
“Disease” specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.
“Fused ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where the ring atoms that are common to both rings are directly bound to each other. Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like. Compounds having fused ring systems may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like.
“Halo” means fluoro, chloro, bromo or iodo.
“Halo-substituted alkyl,” as an isolated group or part of a larger group, means “alkyl” substituted by one or more “halo” atoms, as such terms are defined in this Application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g., halo-substituted (C1-3)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, and the like).
“Heteroatom” refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
“Heteroatom moiety” includes a moiety where the atom by which the moiety is attached is not a carbon. Examples of heteroatom moieties include —N═, —NRc—, —N+(O−)═, —O—, —S— or —S(O)2—, wherein Rc is a further substituent.
“Heterobicycloalkyl” means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example hetero(C9-12)bicycloalkyl as used in this application includes, but is not limited to, 3-aza-bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl, 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.
“Heterocycloalkylene” means cycloallylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.
“Heteroaryl” means a cyclic aromatic group having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized. Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole. “Heteroaryl” also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring. These bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine, pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine, pyrrolo[1,2-a]pyrazine, triazo[1,5-a]pyridine, pteridine, purine, carbazole, acridine, phenazine, phenothiazene, phenoxazine, 1,2-dihydropyrrolo[3,2,1-hi]indole, indolizine, pyrido[1,2-a]indole and 2(1H)-pyridinone. The bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused. The heteroaryl groups of this invention can be substituted or unsubstituted.
“Heterobicycloaryl” means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example, hetero(C8-10)bicycloaryl as used in this Application includes, but is not limited to, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.
“Heterocycloalkyl” means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S. Non-exclusive examples of heterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.
“Hydroxy” means the radical —OH.
“Iminoketone derivative” means a derivative comprising the moiety —C(NR)—, wherein R comprises a hydrogen or carbon atom attached to the nitrogen.
“Isomers” mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers.” A carbon atom bonded to four nonidentical substituents is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of the two enantiomeric forms is termed a “racemic mixture.” A compound that has more than one chiral center has 2n-1 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Calm, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
“Nitro” means the radical —NO2.
“Oxaalkyl” means an alkyl, as defined above, except where one or more oxygen atoms (—O—) are positioned between carbon atoms of the alkyl. For example, a (C2-6)oxaalkyl refers to a chain comprising between 2 and 6 carbons and one or more oxygen atoms positioned between the carbon atoms.
“Oxoalkyl” means an alkyl, further substituted with a carbonyl group. The carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid chloride.
“Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
“Pharmaceutically acceptable salts” means salts of inhibitors of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid; benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.
Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine and the like.
“Prodrug” means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention. The prodrug itself may or may not also have DPP-IV inhibitory activity. For example, an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound. Suitable esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
“Protected derivatives” means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
“Substituted or unsubstituted” means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety. For example, isopropyl is an example of an ethylene moiety that is substituted by —CH3. In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted. Examples of substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, (C1-10)alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.
“Sulfinyl” means the radical —SO—. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.
“Sulfonyl” means the radical —SO2—. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.
“Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
“Thiocarbonyl” means the radical —CS—. It is noted that the thiocarbonyl radical may be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.
“Treatment” or “treating” means any administration of a compound of the present invention and includes:
(1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,
(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease (i.e., arresting further development of the pathology and/or symptomatology), or
(3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology).
It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included. Hence, a C1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom. Hence, a C1 alkyl comprises methyl (i.e., —CH3) as well as —CRaRbRc where Ra, Rb, and Rc may each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano. Hence, CF3, CH2OH and CH2CN, for example, are all C1 alkyls.
The present invention relates to compounds, compositions, kits and articles of manufacture that may be used to inhibit dipeptidyl peptidases IV (referred to herein as DPP-IV).
DPP-IV (EC.3.4.14.5 also known as DPP4, DP4, DAP-IV, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (ADAbp) or CD26) is a 766 residue, 240 kDa protein that is a highly specific membrane bound non-classical serine aminodipeptidase. DPP-IV has a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position. In addition, the slow release of dipeptides of the type X-Gly or X-Ser is reported for some naturally occurring peptides. DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. The wild-type form of full length DPP-IV is described in GenBank Accession Number NM—001935 (“Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation”, Darmoul, D., Lacasa, M., Baricault, L., Marguet, D., Sapin, C., Trotot, P., Barbat, A. and Trugnan, G., J. Biol. Chem., 267 (7), 4824-4833, 1992).
DPP-IV is a member of the S9 family of serine proteases, more particularly the S9B family. Other members of the S9 family include, but are not limited to:
It is noted that the compounds of the present invention may also possess inhibitory activity for other S9 family members and thus may be used to address disease states associated with these other family members.
1. Crystal Structure of DPP-IV
Syrrx, Inc. (San Diego, Calif.) recently solved the crystal structure of DPP-IV. Knowledge of the crystal structure was used to guide the design of the DPP-IV inhibitors provided herein.
2. DPP-IV Inhibitors
In one embodiment, DPP-IV inhibitors of the present invention comprise a compound comprising a formula selected from the group consisting of:
wherein
the broken bonds represent optional bonds between adjacent atoms with available valencies;
L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached;
each W is independently selected from the group consisting of C and N;
each X is independently selected from the group consisting of C, N, O and S;
each Y is independently selected from the group consisting of C, C(O), C(S), C═NR7, N, S, S(O), S(O)2 and O;
each Z is independently selected from the group consisting of C, C(O), C(S), C═NR7, N, S, S(O), S(O)2 and O;
R1 and R2 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, alkyl, cycloalkyl, carbonyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, each substituted or unsubstituted, or a bond with an adjacent atom, or where R1 and R2 are taken together to form a substituted or unsubstituted ring;
R3 is selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R4 comprises the formula -A-Q-D where
R5, R6 and R6′ are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, (C1-4)alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, amino (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or where R6 and R6′ are taken together to form a substituted or unsubstituted ring, with the proviso that R5 is not halogen, cyano, nitro and thio;
R7 and R8 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, amino, alkyl, cycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
R9, R9′, and R10 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, amino, (C1-10)alkyl, amino (C1-3)alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or where R9 and R9′ are taken together to form a substituted or unsubstituted ring;
R11, R11′, and R11″ are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, (C1-4)alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, aryl(C1-4)alkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, thioacetamide, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or where R11′ is a bond with an adjacent atom and R11, or R11 and R11′, are taken together with the carbon to which they are attached to form a substituted or unsubstituted ring;
R12, R13, R14 and R15 are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, (C1-10)alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two of R12, R13, R14 and R15 are taken together to form a substituted or unsubstituted fused or bridged ring, with the proviso that R12, R13, R14 and/or R15 is not present when the ring atom to which R12, R13, R14 or R15 is bound is nitrogen;
R16, R17 and R18 are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two of R16, R17, and R18 are taken together to form a substituted or unsubstituted fused or bridged ring, with the proviso that R16, R17 and/or R18 is not present when the ring atom to which R16, R17 or R18 is bound is nitrogen, oxygen or sulfur;
R19, R19′, R20, R20′, R21, R21′, R22 and R22′ are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two of R19, R19′, R20, R20′, R21, R21′, R22 and R22′ are taken together to form a substituted or unsubstituted fused or bridged ring, with the provisos that (a) only one of R19 and R19′, R20 and R20′, R21 and R21′, and/or R22 and R22′ are present and is not halogen, cyano, nitro or thio when the Y to which the substituent is bound is nitrogen or when adjacent Y form a double bond, and (b) both R19 and R19′, R20 and R20′, R21, and R21′, and/or R22 and R22′ are not present when the Y to which the substituent is bound is C(O), C(S), C═NR8, S, S(O), S(O)2 and O; and
R23, R23′, R24, R24′, R25, and R25′ are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or two of R23, R23′, R24R24′, R25, and R25′ are taken together to form a substituted or unsubstituted fused or bridged ring, with the provisos that (a) only one of R23 and R23′, R24 and R24′, and/or R25 and R25′ are present and is not halogen, cyano, nitro or thio when the Z to which the substituent is bound is nitrogen or when adjacent Z form a double bond, and (b) both R23 and R23′, R24 and R24′, and/or R25 and R25′ are not present when the Z to which the substituent is bound is C(O), C(S), C═NR8, S, S(O), S(O)2 and O.
In another embodiment, DPP-IV inhibitors of the present invention comprise of a formula selected from the group consisting of:
wherein L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached; and R1 to R18 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula selected from the group consisting of:
wherein
L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached;
Y is independently selected from the group consisting of C(O), C(S), C═NR7, N, S, S(O), S(O)2 and O; and R1 to R22 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula selected from the group consisting of:
wherein L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached, Z is independently selected from the group consisting of C, C(O), C(S), C═NR7, S(O), and S(O)2; and R1 to R25 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a compound of formula:
wherein the broken bonds represent optional bonds between adjacent atoms with available valencies; L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached; each W is independently selected from the group consisting of C and N with the proviso that at least one W is N; and R1 to R15 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula selected from the group consisting of:
wherein L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached; and R1 to R15 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula:
wherein L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached; and R1 to R15 are as defined above.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula:
wherein L is a linker providing 1-3 atom separation between —NR1R2 and the ring atom to which L is attached; and R1 to R22 are as defined above.
In one variation of the above embodiment, R2 does not comprise the formula —NHC(O)OC1-4alkyl. In another variation of the above embodiments, D is a secondary amine. In another variation, D is a tertiary amine. In one particular variation, A and D are taken together to form a ring. In yet another variation, the ring formed by taking A and D together is a substituted or unsubstituted 3, 4, 5 or 6 membered ring. In one particular variation, the ring formed by taking A and D together is a substituted or unsubstituted cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C9-12)bicycloaryl, or hetero(C8-12)bicycloaryl.
In yet another variation of the above embodiments, Q and D are taken together to form a ring. In yet another variation, the ring formed by taking Q and D together is a substituted or unsubstituted 3, 4, 5 or 6 membered ring. In another variation, the ring formed by taking Q and D together is a substituted or unsubstituted heterocycloalkyl or phenyl. In another variation, the ring formed by taking Q and D together is a substituted or unsubstituted heteroaryl.
In a particular variation, the ring formed by taking Q and D together causes R4 to comprise the formula
wherein R26 and R26′ are selected from the group consisting of hydrogen, halo, —OH, —NH2, —NO2, —CO2H, (C1-3)alkyl, aryl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, —OCO(C1-3)alkyl, —CO2(C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, and imino group, or R26 and R26′ together are —(CH2)4—.
In another particular variation, A comprises a heterocyclic ring.
In one variation, L and R1 are taken together to form a ring. In another variation, the ring formed by taking L and R1 together is a substituted or unsubstituted 3, 4, 5 or 6 membered ring. In another variation, the ring formed by taking L and R1 together is a substituted or unsubstituted heterocycloalkyl, heteroaryl, or hetero(C8-12)bicycloaryl.
In one variation, the 1-3 atom separation provided by L comprises at least one carbon atom. In another variation, the 1-3 atom separation provided by L consists of carbon atom(s). In yet another variation, the 1-3 atom separation provided by L comprises at least one oxygen, or at least one nitrogen atom. In yet another variation, the 1-3 atom separation provided by L consists of an oxygen or nitrogen atom. In another variation, L is a linker providing a 1 atom separation between —NR1R2 and the ring atom to which L is attached. In yet another variation, L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —C(O)—, —CH2C(O)—, —C(O)CH2—, —CH2—C(O)CH2—, —C(O)CH2CH2—, —CH2CH2C(O)—, —O—, —OCH2—, —CH2O—, —CH2OCH2—, —OCH2CH2—, —CH2CH2O—, —N(CH3)—, —NHCH2—, —CH2NH—, —CH2NHCH2—, —NHCH2CH2—, —CH2CH2NH—, —NH—C(O)—, —NCH3—C(O)—, —C(O)NH—, —C(O)NCH3—, —NHC(O)CH2—, —C(O)NHCH2—, —C(O)CH2NH—, —CH2NHC(O)—, —CH2C(O)NH—, —NHCH2C(O)—, —CH2SCH2—, —SC(O)—, —C(O)SCH2—, and —CH2SC(O)—, each substituted or unsubstituted.
In one particular variation, L is —CR27R27′— wherein R27 and R27′ are each independently selected from the group consisting of hydrogen, halogen, perhalo(C1-10)alkyl, amino, cyano, nitro, thio, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or where R27 and R27′ are taken together to form a substituted or unsubstituted ring, with the proviso that at least one of R27 and R27′ is not hydrogen. In another variation, L is —O—.
In another variation, L is —NR28— wherein R28 is independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, amino, alkyl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group, and sulfinyl group, each substituted or unsubstituted.
In one variation, R1 is selected from the group consisting of hydrogen, amino, alkyl, cycloalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted. In another variation, R1 is hydrogen. In yet another variation, R1 is a thiazolyl group.
In one variation of the above embodiments, R1 is selected from the group consisting of —OH, —NH2, —COOH, (C1-3)alkyl, 2-nitrophenyl, 4-MeSO2-phenyl, 2-cyanophenyl, 4-cyanophenyl, 4-nitrophenyl, 2-nitro-4-cyanophenyl, 2-nitro-pyridin-2-yl, 4-halo-2-cyanophenyl, cycloalkyl, heterocycloalkyl, 4-heteroaryl-piperazin-1-yl, 4-(C9-12)bicycloheteroaryl-piperazin-1-yl, bicycloalkyl, aryl(C1-3)alkyl, heteroaryl(C1-3) (C1-3)alkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, —CO2(C1-4)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, carbonyl group, and imino group, each substituted or unsubstituted.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula selected from the group consisting of:
wherein:
R1 and R2 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, (C1-3)alkyl, cycloalkyl, (C1-4)alkylOCO, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, (C1-3)alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, each substituted or unsubstituted, or a bond with an adjacent atom, or where R1 and R2 are taken together to form a substituted or unsubstituted ring;
R26 and R26′ are selected from the group consisting of hydrogen, halo, —OH, —NH2, —CO2H, (C1-3)alkyl, aryl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, aminocarbonyl, thiocarbonyl (C1-3)alkyl, —OCO(C1-3)alkyl, —CO2(C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl(C1-3)alkyl, imino (C1-3)alkyl, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, aryl, heteroaryl, (C9-12)bicyoloaryl, hetero(C8-12)bicycloaryl, or R26 and R26′ together are —(CH2)4—;
R27 is selected from the group consisting of hydrogen, halo, perhalo(C1-10)alkyl, (C1-3)alkoxy(C1-3)alkylamino, (C1-3)alkoxyaryl(C1-3)alkylamino, (C1-3)alkyl, cycloalkyl, aryl(C1-3)alkyl[(C1-3)alkyl]amino, heteroaryl(C1-3)alkyl[(C1-3)alkyl]amino, heterocycloalkyl, heterobicycloalkyl, bicycloalkyl, aryl(C1-3)alkyl, heteroaryl(C1-3)alkyl, carbonyl(C1-3)alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, perhalo(C1-10)alkylCO, cycloalkylCO, (C1-3)alkoxy(C1-3)alkylCO, (C1-3)alkoxyaryl(C1-3)alkylCO, aryl(C1-3)alkyl[(C1-3)alkyl]CO, heteroaryl(C1-3)alkyl[(C1-3)alkyl]CO, and (C1-4)alkylCO, each substituted or unsubstituted; and
R28 and R29 are each independently selected from the group consisting of hydrogen, (C1-3)alkyl, (C1-3)alkyl perhalo(C1-10)alkylCO, (C1-3)alkylCO, cycloalkylCO, (C1-4)alkylOCO, (C1-3)alkoxy(C1-3)alkylCO, (C1-3)alkoxyaryl(C1-3)alkylCO, (C1-3)alkyl, cycloalkyl, aryl(C1-3)alkyl[(C1-3)alkyl]CO, heteroaryl(C1-3)alkyl[(C1-3)alkyl]CO, imino (C1-3)alkyl, aryl, heteroaryl, each substituted or unsubstituted.
In another embodiment, DPP-IV inhibitors of the present invention comprise a formula selected from the group consisting of:
wherein:
R1 and R2 are each independently selected from the group consisting of hydrogen, perhalo(C1-10)alkyl, (C1-3)alkyl, cycloalkyl, (C1-4)alkylOCO, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, hydroxy, (C1-3)alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, each substituted or unsubstituted, or a bond with an adjacent atom;
R26 and R26′ are selected from the group consisting of hydrogen, halo, —OH, —NH2, —CO2H, (C1-3)alkyl, aryl, cycloalkyl, heterocycloalkyl, bicycloalkyl, arylalkyl, heteroarylalkyl, carbonyl (C1-3)alkyl, thiocarbonyl (C1-3)alkyl, —OCO(C1-3)alkyl, —CO2(C1-3)alkyl, sulfonyl (C1-3)alkyl, sulfinyl (C1-3)alkyl, imino (C1-3)alkyl, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, aryl, heteroaryl, (C9-12)bicycloaryl, hetero(C8-12)bicycloaryl, or R26 and R26′ together are —(CH2)4—.
R27 is selected from the group consisting of perhalo(C1-10)alkyl, (C1-3)alkoxy(C1-3)alkylamino, (C1-3)alkoxyaryl(C1-3)alkylamino, (C1-3)alkyl, cycloalkyl, aryl(C1-3)alkyl[(C1-3)alkyl]amino, heteroaryl(C1-3)alkyl[(C1-3)alkyl]amino, heterocycloalkyl, heterobicycloalkyl, bicycloalkyl, aryl(C1-3)alkyl, heteroaryl(C1-3)alkyl, carbonyl(C1-3)alkyl, alkoxy, aryloxy, heteroaryloxy, alkene, alkyne, aryl, heteroaryl, (C9-12)bicycloaryl, and hetero(C8-12)bicycloaryl, each substituted or unsubstituted; and
R28 and R29 are each independently selected from the group consisting of hydrogen, (C1-3)alkyl, (C1-3)alkyl perhalo(C1-10)alkylCO, (C1-3)alkylCO, cycloalkylCO, (C1-3)alkoxy(C1-3)alkylCO, (C1-3)alkoxyaryl(C1-3)alkylCO, (C1-3)alkyl, cycloalkyl, aryl(C1-3)alkyl[(C1-3)alkyl]CO, heteroaryl(C1-3)alkyl[(C1-3)alkyl]CO, imino (C1-3)alkyl, aryl, heteroaryl, each substituted or unsubstituted.
Particular Examples of DPP-IV Inhibitors
Particular examples of DPP-IV inhibitors according to the present invention include, but are not limited to:
In another embodiment, the present invention provides the compounds in the form of a pharmaceutically acceptable salt.
In yet another embodiment, the present invention provides the compounds present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer.
In yet another embodiment, the present invention provides pharmaceutical compositions comprising the compound as an active ingredient. In yet another variation, the present invention provides pharmaceutical compositions wherein the compositions are solid formulations adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical compositions wherein the compositions are tablets. In another particular variation, the present invention provides pharmaceutical compositions wherein the compositions are liquid formulations adapted for oral administration. In yet another particular variation, the present invention provides pharmaceutical compositions wherein the compositions are liquid formulations adapted for parenteral administration.
In yet another particular variation, the present invention provides pharmaceutical compositions comprising the compounds of the invention wherein the compositions are adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.
In another embodiment, the present invention provides a kit comprising a compound of the present invention and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound. In another embodiment, the present invention provides the kit that comprises the compound in a multiple dose form.
In another embodiment, the present invention provides an article of manufacture comprising a compound of the present invention, and packaging materials. In another variation, the packaging material comprises a container for housing the compound. In yet another variation, the invention provides the article of manufacture wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
In another variation, the present invention provides the article of manufacture wherein the article of manufacture comprises the compound in a multiple dose form.
In another embodiment, the present invention provides a method of inhibiting DPP-IV comprising contacting DPP-IV with a compound according to the present invention.
In another embodiment, the present invention provides a method of inhibiting DPP-IV comprising causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
In another embodiment, the present invention provides a method of inhibiting DPP-IV comprising:
administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo, the second compound being a compound of the present invention.
In another embodiment, the present invention provides therapeutic method comprising administering a compound according to the present invention to a subject.
In another embodiment, the present invention provides a method of treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound of the present invention to be present in a subject in a therapeutically effective amount for the disease state.
In another embodiment, the present invention provides a method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
In another embodiment, the present invention provides a method of treating a disease where the disease is type I or type II diabetes.
In another embodiment, the present invention provides a method of treating autoimmune disorders such as, but not limited to, rheumatoid arthritis, psoriasis, and multiple sclerosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
In yet another embodiment, the present invention provides a method of treating cancer where the cancer treated is colorectal, prostate, breast, thyroid, skin, lung, or head and neck.
In another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemopoietic cell activation or concentration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
In another embodiment, the present invention provides a method of treating HIV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a side effect of chemotherapy or radiation therapy.
In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of kidney failure.
In yet another embodiment, the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of a bone marrow disorder.
In another embodiment, the present invention provides a method of treating a condition characterized by immunodeficiency symptoms in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
It is noted in regard to all of the embodiments, and any further embodiments, variations, or individual compounds described or claimed herein that all such embodiments, variations, and/or individual compounds are intended to encompass all pharmaceutical acceptable salt forms whether in the form of a single stereoisomer or mixture of stereoisomers unless it is specifically specified otherwise. Similarly, when one or more potentially chiral centers are present in any of the embodiments, variations, and/or individual compounds specified or claimed herein, both possible chiral centers are intended to be encompassed unless it is specifically specified otherwise.
A. Salts, Hydrates, and Prodrugs of DPP-IV Inhibitors
It should be recognized that the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention. For example, it is within the scope of the present invention to convert the compounds of the present invention into and use them in the form of their pharmaceutically acceptable salts derived from various organic and inorganic acids and bases in accordance with procedures well known in the art.
When the compounds of the present invention possess a free base form, the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate. Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate and phthalate. It should be recognized that the free base forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base forms for the purposes of the present invention.
When the compounds of the present invention possess a free acid form, a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Examples of such bases are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine. Also included are the aluminum salts of the compounds of the present invention. Further base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)-methylamine (tromethamine). It should be recognized that the free acid forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid forms for the purposes of the present invention.
Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C1-4) alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides, bromides and iodides; di (C1-4) alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C10-18) alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C1-4) alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such salts permit the preparation of both water-soluble and oil-soluble compounds of the present invention.
N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C. Alternatively, the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention. For example, prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.
Protected derivatives of compounds of the present invention can also be made. Examples of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
Compounds of the present invention may also be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxane, tetrahydrofuran or methanol.
A “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound. The pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized. One of skill in the art will appreciate that an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.
3. Preparation of DPP-IV Inhibitors
Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise.
It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.
Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
4. Indications for Use of DPP-IV Inhibitors
DPP-IV is believed to contribute to the pathology and/or symptomology of several different diseases such that reduction of the activity of DPP-IV in a subject through inhibition may be used to therapeutically address these disease states. Examples of various diseases that may be treated using the DPP-IV inhibitors of the present invention are described herein. It is noted that additional diseases beyond those disclosed herein may be later identified as the biological roles that DPP-IV plays in various pathways becomes more fully understood.
One set of indications that DPP-IV inhibitors of the present invention may be used to treat are those involving the prevention and treatment of diabetes and obesity, in particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
DPP-IV inhibitors of the present invention may also be used as immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
DPP-IV inhibitors of the present invention may also be used for treating various cancers including breast cancer, lung cancer and prostate cancer.
DPP-IV inhibitors of the present invention may also be used to treat dermatological diseases such as psoriasis, rheumatoid arthritis (RA) and lichen planus.
DPP-IV inhibitors of the present invention may also be used to treat infertility and amenorrhea.
DPP-IV inhibitors of the present invention may also be used to modulate cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. For example, such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer.
DPP-IV inhibitors of the present invention may also be used prevent or reduce cleavage of N-terminal Tyr-Ala from growth hormone-releasing factor. Accordingly, these inhibitors may be used in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth.
DPP-IV inhibitors of the present invention may also be used to address disease states associated with cleavage of neuropeptides and thus may be useful for the regulation or normalization of neurological disorders.
For oncology indications, DPP-IV inhibitors of the present invention may be used in conjunction with other agents to inhibit undesirable and uncontrolled cell proliferation. Examples of other anti-cell proliferation agents that may be used in conjunction with the DPP-IV inhibitors of the present invention include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN™ protein, ENDOSTATIN™ protein, suramin, squalamine, tissue inhibitor of metalloproteinase-I, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel, platelet factor 4, protamine sulfate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA)), cishydroxyproline, d,1-3,4-dehydroproline, thiaproline, beta.-aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin, beta.-cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodium thiomalate, d-penicillamine (CDPT), beta.-1-anticollagenase-serum, alpha.2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or “CCA”, thalidomide; angostatic steroid, carboxyaminoimidazole; metalloproteinase inhibitors such as BB94. Other anti-angiogenesis agents that may be used include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: bFGF, aFGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. Ferrara N. and Alitalo, K. “Clinical application of angiogenic growth factors and their inhibitors” (1999) Nature Medicine 5:1359-1364.
5. Compositions Comprising DPP-IV Inhibitors
A wide variety of compositions and administration methods may be used in conjunction with the DPP-IV inhibitors of the present invention. Such compositions may include, in addition to the DPP-IV inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents. Additionally, the compositions may include active agents in addition to the DPP-IV inhibitors of the present invention. These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.
The compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used. For oral administration, capsules and tablets are typically used. For parenteral administration, reconstitution of a lyophilized powder, prepared as described herein, is typically used.
Compositions comprising DPP-IV inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.
The DPP-IV inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form. Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a DPP-IV inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome. Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid. Parenteral preparations may optionally be enclosed in ampules, disposable syringes or single or multiple dose vials made of glass, plastic or other suitable material.
When DPP-IV inhibitors according to the present invention exhibit insufficient solubility, methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
Upon mixing or adding DPP-IV inhibitors according to the present invention to a composition, a solution, suspension, emulsion or the like may be formed. The form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle. The effective concentration needed to ameliorate the disease being treated may be empirically determined.
Compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms, as used herein, refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes and individually packaged tablet or capsule. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit-doses that are not segregated in packaging.
In addition to one or more DPP-IV inhibitors according to the present invention, the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polyinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Actual methods of preparing such dosage forms are known in the art, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a sufficient quantity of a DPP-IV inhibitor of the present invention to reduce DPP-IV activity in vivo, thereby treating the disease state of the subject.
Dosage forms or compositions may optionally comprise one or more DPP-IV inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein. For oral administration, a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum. Such compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art. The compositions may optionally contain 0.01%-100% (weight/weight) of one or more DPP-IV inhibitors, optionally 0.1-95%, and optionally 1-95%.
Salts, preferably sodium salts, of the DPP-IV inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. The formulations may further include other active compounds to obtain desired combinations of properties.
A. Formulations for Oral Administration
Oral pharmaceutical dosage forms may be as a solid, gel or liquid. Examples of solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated. Examples of capsules include hard or soft gelatin capsules. Granules and powders may be provided in non-effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.
In certain embodiments, DPP-IV inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets. The tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.
Examples of binders that may be used include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.
Examples of lubricants that may be used include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
Examples of glidants that may be used include, but are not limited to, colloidal silicon dioxide.
Examples of disintegrating agents that may be used include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.
Examples of coloring agents that may be used include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
Examples of sweetening agents that may be used include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.
Examples of flavoring agents that may be used include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.
Examples of wetting agents that may be used include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
Examples of anti-emetic coatings that may be used include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
Examples of film coatings that may be used include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
If oral administration is desired, the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.
When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil. In addition, dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The DPP-IV inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. For example, if a compound is used for treating asthma or hypertension, it may be used with other bronchodilators and antihypertensive agents, respectively.
Examples of pharmaceutically acceptable carriers that may be included in tablets comprising DPP-IV inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents. Enteric-coated tablets, because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines. Sugar-coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied. Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges.
Examples of liquid oral dosage forms that may be used include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
Examples of aqueous solutions that may be used include, but are not limited to, elixirs and syrups. As used herein, elixirs refer to clear, sweetened, hydroalcoholic preparations. Examples of pharmaceutically acceptable carriers that may be used in elixirs include, but are not limited to solvents. Particular examples of solvents that may be used include glycerin, sorbitol, ethyl alcohol and syrup. As used herein, syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.
Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in-water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.
Examples of pharmaceutically acceptable substances that may be used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.
Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide.
Coloring and flavoring agents may optionally be used in all of the above dosage forms.
Particular examples of preservatives that may be used include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
Particular examples of non-aqueous liquids that may be used in emulsions include mineral oil and cottonseed oil.
Particular examples of emulsifying agents that may be used include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
Particular examples of suspending agents that may be used include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.
Particular examples of wetting agents that may be used include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
Particular examples of organic acids that may be used include citric and tartaric acid.
Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate.
Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
Particular examples of flavoring agents that may be used include natural flavors extracted from plants such as fruits, and synthetic blends of compounds that produce a pleasant taste sensation.
For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.
Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.
B. Injectables, Solutions and Emulsions
The present invention is also directed to compositions designed to administer the DPP-IV inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
Examples of excipients that may be used in conjunction with injectables according to the present invention include, but are not limited to water, saline, dextrose, glycerol or ethanol. The injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795), is also contemplated herein. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.
When administered intravenously, examples of suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
Examples of aqueous vehicles that may optionally be used include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
Examples of nonaqueous parenteral vehicles that may optionally be used include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
Examples of isotonic agents that may be used include sodium chloride and dextrose. Examples of buffers that may be used include phosphate and citrate. Examples of antioxidants that may be used include sodium bisulfate. Examples of local anesthetics that may be used include procaine hydrochloride. Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80). A sequestering or chelating agent of metal ions include EDTA.
Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
The concentration of a DPP-IV inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect. The exact concentration of a DPP-IV inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is known and practiced in the art.
Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or, more preferably, more than 1% w/w of the DPP-IV inhibitor to the treated tissue(s). The DPP-IV inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
The DPP-IV inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.
C. Lyophilized Powders
The DPP-IV inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. The lyophilized powders may also be formulated as solids or gels.
Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH. Then, a DPP-IV inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35° C., and stirred until it dissolves. The resulting mixture is diluted by adding more buffer to a desired concentration. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial may contain a single dosage or multiple dosages of the DPP-IV inhibitor.
D. Topical Administration
The DPP-IV inhibitors of the present invention may also be administered as topical mixtures. Topical mixtures may be used for local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
The DPP-IV inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.
The DPP-IV inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the DPP-IV inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.
E. Formulations for Other Routes of Administration
Depending upon the disease state being treated, other routes of administration, such as topical application, transdermal patches, and rectal administration, may also be used. For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein to mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
F. Examples of Formulations
The following are particular examples of oral, intravenous and tablet formulations that may optionally be used with compounds of the present invention. It is noted that these formulations may be varied depending on the particular compound being used and the indication for which the formulation is going to be used.
6. Kits Comprising DPP-IV Inhibitors
The invention is also directed to kits and other articles of manufacture for treating diseases associated with DPP-IV. It is noted that diseases are intended to cover all conditions for which the DPP-IV possesses activity that contributes to the pathology and/or symptomology of the condition.
In one embodiment, a kit is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.
In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.
It is noted that the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
One particular example of a kit according to the present invention is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise.
It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.
Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.
The free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
The N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C. Alternatively, the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
Compounds in an unoxidized form can be prepared from N-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80° C.
Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like).
Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
Compounds according to the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:
All references to ether or Et2O are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in ° C. (degrees Centigrade). All reactions conducted under an inert atmosphere at RT unless otherwise noted.
1H NMR spectra were recorded on a Bruker Avance 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of Hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad).
Low-resolution mass spectra (MS) and compound purity data were acquired on a Waters ZQ LC/MS single quadrupole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm), and evaporative light scattering detector (ELSD). Thin-layer chromatography was performed on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid, Ninhydrin or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck).
The entire disclosure of all documents cited throughout this application are incorporated herein by reference.
DPP-IV inhibitors according to the present invention may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided herein in the examples. Other reaction schemes could be readily devised by those skilled in the art.
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in “Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.
Compounds according to the present invention may optionally be synthesized according to the following general reaction schemes, and the schemes are applicable to all of the representative compounds disclosed herein:
In each of the above reaction schemes, the various substituents may be selected from among the various substituents otherwise taught herein.
Descriptions of the syntheses of particular compounds according to the present invention based on the above reaction scheme are set forth herein.
The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or may be prepared by methods well known to a person of ordinary skill in the art, following procedures described in such standard references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons, New York, N.Y., 1991; March J.: Advanced Organic Chemistry, 4th ed., John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive Organic Transformations, VCH Publishers, New York, 1989.
The present invention is further exemplified, but not limited by, the following examples that describe the synthesis of particular compounds according to the invention.
Silica gel (5 g) and MnO2 (4.60 g, 52.9 mmol) were ground to a homogenous consistency and the mixture was added to a solution of 1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-6,8-dimethoxy-3,4-dihydro-isoquinoline-4-carboxylic acid ethyl ester (Note 1) (1.39 g, 3.53 mmol) in 180 mL of benzene. The reaction flask, equipped with a Dean-Stark trap and a condenser, was then heated to 100° C., with azeotropic removal of water (18 ml). After 4 hours, the reaction was cooled to room temperature and filtered through a plug of celite, rinsing with 3% MeOH in DCM. The filtrate was concentrated to give 1.30 g (94%) of 1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester as a white solid. H1-NMR (CDCl3): δ, 8.85 (s, 1H), 8.07 (d, 111, J=2.1 Hz), 7.92 (m, 2H), 7.75 (m, 2H), 6.62 (d, 1H, J=2.4 Hz), 5.62 (s, 2H), 4.36 (q, 2H, J=7.4), 4.03 and 3.98 (s, 3H each), 1.36 (t, 3H, J=6.9 Hz).
Note 1: Coppola et al. Heterocycl. Comm. 2000, 6, 13.
To a solution of 1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester (1.22 g, 2.90 mmol) in 80 mL of absolute ethanol hydrazine monohydrate (1.59 g, 31.8 mmol) was added and the mixture was stirred under a nitrogen atmosphere at 40° C. After 4 h, the reaction was cooled to room temperature, and the phthalhydrazide precipitate was removed by filtration, rinsing with ethanol. The filtrate was concentrated under reduced pressure to give 1.04 g of crude 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester, which was used directly the next step. H1-NMR (DMSO): δ, 8.84 (s, 1H), 7.81 (d, 1, J=2.4 Hz), 6.76 (d, 1H, J=2.3 Hz), 4.36 (q, 2H, J=7.13), 4.32 (s, 2H), 3.95 and 3.88 (s, 3H each), 1.35 (t, 3H, J=7.2 Hz); MS: APCI (M+H) calc'd for C15H18N2O4+H 291.3; found 291.1.
A solution of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester (1.04 g, 3.59 mmol) and 0.750 mL (1.5 eq) of TEA in 30 mL of THF was stirred at room temperature. A solution of Boc anhydride (940 mg, 4.3 mmol) in 10 mL of diethyl ether was added and the reaction was stirred under nitrogen for 15 hours. The reaction was diluted with 50 mL of EtOAc and then washed with 50 mL of water. The aqueous phase was extracted with EtOAc (2×20 mL) and the combined organics were washed with saturated sodium bicarbonate, and then with brine. The organic phase was dried with magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography eluting with 3% MeOH in DCM to give 1.08 g (77%) of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester. H1-NMR (CDCl3): δ 9.01 (s, 1H), 8.06 (s, 1H), 6.78 (s, 1H), 6.59 (s, 1H), 5.07 (s, 2H), 4.45 (q, 2H, J=7.1), 3.98 (m, 6H), 1.50 (m, 12H); MS: APCI (M+H) calc'd for C20H26N2O6+H 391.4; found 391.0.
To a solution of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester (520 mg, 1.34 mmol) in THF (10 ml) and H2O (10 ml) under nitrogen, LiOH—H2O (95 mg, 2.3 mmol) was added. The reaction was stirred at 50° C. for 3.5 hours and at then at room temperature for 18 hours. EtOAc and water were then added and the pH was adjusted to 5 by dropwise addition of 6N HCl. The layers were then separated and the aqueous phase was extracted with EtOAc. The combined organic layers were then washed with brine, dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure to give 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid as a solid (464 mg, 96%). H1-NMR (DMSO): δ, 8.84 (s, 1H), 7.96 (s, 1H), 6.91 (t, 1H, J=5.4 Hz), 6.77 (s, 1H), 4.80 (d, 2H, J=5.43 Hz), 3.95 and 3.88 (s, 3H each), 1.36 (s, 9H).
According to the procedure of Yamada et al. (Note 2), a solution of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid (100 mg, 0.3 mmol) and 1,2,3,4-tetrahydro-isoquinoline (44 mg, 0.33 mmol) in 5 mL of THF was stirred at 0° C. under a nitrogen atmosphere. Diethyl cyanophosphonate (54 mg, 0.33 mmol) in 2 mL of THF was added followed by triethylamine (77 μL, 0.55 mmol). The reaction was stirred at 0° C. for 30 minutes and then at room temperature for 15 h. The reaction was diluted with EtOAc and then washed with water. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with NH4OH (10% solution in H2O) and then with brine. The organic layer was then dried over magnesium sulfate, filtered and concentrated. The resulting residue was triturated with ether to give 87 mg (66%) of the desired product. H1-NMR (CDCl3): δ 8.30 (s, 1H), 7.27 (broad m, 4H), 6.75 (m, 1H), 6.58 (m, 2H), 5.09 (m, 2H), 4.41 (m, 2H), 3.98 (m, 2H), 3.83 (s, 2H), 3.50 (s, 3H), 3.09 and 2.77 (m, 1H each), 1.52 (s, 9H), [Note: broadening of peaks observed due to Boc group, rotamers also observed.] MS: APCI (M+H) calc'd for C27H31N3O5+H 478.6; found 478.0.
Note 2: Yamada et al. Tetrahedron Letters 1973, 1595.
A solution of [4-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (79 mg, 0.17 mmol) in 3 mL of EtOAc was stirred at room temperature, and 2 mL of HCl (3.2 M in EtOAc) was added. After stirring at room temperature overnight (deprotection is typically complete after 4-8 hours) the solvent was removed under reduced pressure and the residue was triturated with ether to give 75 mg of product as the HCl salt. H1-NMR (DMSO): δ, 8.42 (br s, 1H), 7.18 (m, 4H), 6.60 (m, 2H), 4.65 (br s, 2H), 4.27 (m, 2H), 3.98 (br s, 3H), 3.80 (s, 3H), 3.39 (m, 3H), 3.86 (m, 2H), [Note: Rotamers observed.] MS: APCI (M+H) calc'd for C22H23N3O3+H 378.4; found 378.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with 2-methoxy-ethylamine to give 92 mg of [6,8-dimethoxy-4-(2-methoxy-ethylcarbamoyl)-isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester. H1-NMR (CDCl3): δ, 8.46 (s, 1H), 7.34 (s, 1H), 6.73 (br s, 1H), 6.59 (s, 1H), 6.51 (br s, 1H), 5.03 (d, J=3.9 Hz, 2H), 3.98 (s, 3H), 3.95 (s, 3H), 3.75 (q, J=5.1 Hz, 2H), 3.65 (t, J=5.1 Hz, 2H), 3.43 (s, 3H), 1.54 (s, 9H).
Step B: As described in example 1, 92 mg of [6,8-dimethoxy-4-(2-methoxy-ethylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 22 mg (32%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid (2-methoxy-ethyl)-amide. H1-NMR (Free base) (CDCl3): δ, 8.47 (s, 1H), 7.33 (s, 1H), 6.63 (s, 1H), 6.57 (s, 1H), 4.45 (s, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.73 (q, J=4.8 Hz, 2H), 3.63 (d, J=5.1 Hz, 2H), 3.61 (s, 3H), 3.40 (s, 3H); MS: APCI (M+H) calc'd for C16H21N3O4+H 320.4; found 320.2.
Step A: As described in example 1E, 50 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with 4-methoxy-benzylamine to give 48 mg of [6,8-dimethoxy-4-(4-methoxy-benzylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester. H1-NMR (CDCl3): δ, 8.43 (s, 1H), 7.35 (d, J=8.6 Hz, 2H), 6.91 (d, J=8.6 Hz, 2H), 6.87 (s, 1H), 6.68 (br s, 1H), 6.56 (s, 1H), 6.36 (br s, 1H), 5.00 (d, J=3.5 Hz, 2H), 4.66 (d, J=5.9 Hz, 2H), 3.95 (s, 3H), 3.88 (s, 3H), 3.82 (s, 3H), 1.51 (s, 9H); MS: APCI (M+H) calc'd for C26H31N3O6+H 482.5; found 482.0.
Step B: As described in example 1, 46 mg of [6,8-dimethoxy-4-(4-methoxy-benzylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 20 mg (54%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid 4-methoxy-benzylamide hydrochloride. H1-NMR (DMSO): δ 9.26 (br s, 3H), 8.41 (s, 1H), 8.38 (br s, 1H), 7.31 (d, J=8.2 Hz, 2H), 7.09 (s, 1H), 6.90 (d, J=8.2 Hz, 2H), 6.81 (s, 1H), 4.67 (d, J=5.1 Hz, 2H), 4.44 (d, J=5.5 Hz, 2H), 3.96 (s, 3H), 3.76 (s, 3H), 3.71 (s, 3H); MS: APCI (M+H) calc'd for C21H23N3O4+H 382.4; found 382.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with benzyl-methyl-amine to give 100 mg of [4-(benzyl-methyl-carbamoyl)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C26H31N3O5+H 466.5; found 466.0.
Step B: As described in example 1, 100 mg of [4-(benzyl-methyl-carbamoyl)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 106 mg (>100%) of the hydrochloride salt. H1-NMR (DMSO): δ 8.42 (s, 1H), 8.38 (s, 3H), 7.52-7.12 (m, 5H), 7.12 (s, 1H), 6.84 (s, 1H), 6.80 (s, 1H), 6.63 (s, 1H), 6.40 (s, 1H), 4.67 (d, J=4.7 Hz, 2H), 3.96 (s, 5H), 3.89 (s, 3H), 3.64 (s, 4H), 3.02 (s, 2H), 2.67 (s, 4H); MS: APCI (M+H) calc'd for C2H23N3O3+H 366.4; found 366.2.
Step A: As described in example 1E, 76 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with 2,3-dihydro-1H-isoindole to give 75 mg of [4-(1,3-dihydro-isoindole-2-carbonyl)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C26H29N3O5+H 464.5; found 464.0.
Step B: As described in example 1, 61 mg of [4-(1,3-dihydro-isoindole-2-carbonyl)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 59 mg (>100%) of (1-aminomethyl-6,8-dimethoxy-isoquinolin-4-yl)-(1,3-dihydro-isoindol-2-yl)-methanone hydrochloride. H1-NMR (DMSO): δ, 8.49 (s, 1H), 8.43 (br s, 3H), 7.42-7.15 (m, 4H), 6.85 (s, 1H), 6.74 (s, 1H), 4.97 (s, 2H), 4.70 (d, J=4.7 Hz, 2H), 4.49 (s, 2H), 3.99 (s, 3H), 3.82 (s, 3H); MS: APCI (M+H) calc'd for C21H21N3O3+H 364.4; found 364.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with methyl-(2-pyridin-2-yl-ethyl)-amine to give 66 mg of {6,8-dimethoxy-4-[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C26H32N4O5+H 481.6; found 481.0.
Step B: As described in example 1, 57 mg of {6,8-dimethoxy-4-[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 74 mg (>100%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide hydrochloride. MS: APCI (M+H) calc'd for C21H24N4O3+H 381.4; found 381.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with methyl-pyridin-3-ylmethyl-amine to give 98 mg of [6,8-dimethoxy-4-(methyl-pyridin-3-ylmethyl-carbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C20H22N4O3+H 367.2; found 367.2.
Step B: As described in example 1, 88 mg of [6,8-dimethoxy-4-(methyl-pyridin-3-ylmethyl-carbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 102 mg (>100%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid methyl-pyridin-3-ylmethyl-amide hydrochloride. MS: APCI (M+H) calc'd for C21H24N4O3+H 381.4; found 381.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with methyl-(1-phenyl-ethyl)-amine to give 112 mg of {6,8-dimethoxy-4-[methyl-(1-phenyl-ethyl)-carbamoyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C27H33N3O5+H 480.6; found 480.0.
Step B: As described in example 1, 112 mg of {6,8-dimethoxy-4-[methyl-(1-phenyl-ethyl)-carbamoyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 86 mg (97%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid methyl-(1-phenyl-ethyl)-amide hydrochloride. MS: APCI (M+H) calc'd for C22H25N3O3+H 380.5; found 380.2.
Step A: As described in example 1E, 100 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid was coupled with N'-benzyl-N,N-dimethyl-ethane-1,2-diamine to give 98 mg of {4-[benzyl-(2-dimethylamino-ethyl)-carbamoyl]-6,8-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C29H38H4O5+H 523.6; found 523.0.
Step B: As described in example 1, 91 mg of {4-[benzyl-(2-dimethylamino-ethyl)-carbamoyl]-6,8-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 74 mg (>100%) of 1-aminomethyl-6,8-dimethoxy-isoquinoline-4-carboxylic acid benzyl-(2-dimethylamino-ethyl)-amide MS: APCI (M+H) calc'd for C24H30N4O3+H 423.5; found 423.2.
A stirred solution of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid (115 mg, 0.317 mmol) in 8 mL of dioxane, at room temperature, was treated with 49 mg (0.380 mmol, 1.2 eq) diisopropylethyl amine and allowed to stir for 5 minutes. Diphenylphosphoryl azide (96 mg, 1.02 eq) was added dropwise and the reaction was heated to 95° C. After 30 minutes, the reaction was removed from heat, and 46 mg (0.380 1.2 eq) of N-methyl, N-benzylamine was added. The reaction was then heated at 75° C. for 4 h. After cooling to room temperature, the solution was diluted with 15 mL of EtOAc, and was washed sequentially with water, then 1% NH4OH, then brine. The organic phase was dried over MgSO4, filtered through a plug of silica and concentrated. The product was purified by flash chromatography, eluting with 1% MeOH in DCM, to give 101 mg, 66% of the desired urea, as white solid. H1-NMR (CDCl3): δ 8.35 (s, 1H), 7.3-7.4 (m, 5H), 6.77 (s, 1H), 6.45 (s, 1H), 6.34 (s, 1H), 6.30 (s, 1H), 4.94 (d, J=4.7 Hz, 2H), 4.65 (s, 2H), 3.92 (s, 3H), 3.71 (s, 3H), 3.15 (s, 3H), 1.51 (s, 9H). MS: APCI (M+H) calc'd for C26H32N4O5+H=481.6; found 481.0.
To a solution of [4-(3,3-dimethyl-ureido)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (90 mg) in 2 mL of EtOAc, 1 mL of 3.2 M HCl in EtOAc was added dropwise. A white solid was evident within an hour and the reaction was allowed to stir, at room temperature, overnight. The solvent was removed in vacuo, and the resulting white solid was washed with ether and collected by filtration to give 55 mg (70%) of the desired amine-hydrochloride. MS: APCI (M+H) calc'd for C21H24N4O3+H 381.4; found 381.1.
According to Example 10A, 102 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid furnished 92 mg (66%) of the urea. H1-NMR (CDCl3): δ 8.37 (s, 1H), 7.3-7.5 (m, 5H), 6.77 (s, 1H), 6.44 (s, 1H), 6.23 (s, 2H), 4.93 (s, 2H), 4.65 (s, 2H), 3.91 (s, 3H), 3.66 (s, 3H), 3.57 (q, 2H) 1.51 (s, 9H), 1.24 (t, 3H). MS: APCI (M+H) calc'd for C26H32N4O5+H=480.6; found 480.0.
A solution of the Boc protected amine (82 mg) in 2 mL of EtOAc was treated as described in example 10, to give 51 mg (71%) of the desired amine hydrochloride. MS: APCI (M+H) calc'd for C22H26N4O3 395.5; found 395.1.
According to Example 10A, 102 mg of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid furnished 88 mg (65%) of the urea. H1-NMR (CDCl3): δ 8.59 (s, 1H), 8.56, (d, 1H), 8.30 (s, 1H), 7.70 (m, 1H), 7.29 (m, 2H) 6.74 (s, 1H), 6.51 (s, 1H), 6.46 (d, 1H), 4.92 (s, 2H), 4.65 (s, 2H), 3.92 (s, 3H), 3.82 (s, 3H), 3.11 (s, 3H), 1.51 (s, 9H). MS: APCI (M+H) calc'd for C25H31N5O5+H=482.5; found 482.0.
A solution of the Boc protected amine (78 mg) in 2 mL of EtOAc was treated as described in example 10, to give 44 mg (65%) of the desired amine hydrochloride. MS: APCI (M+H) calc'd for C20H23N5O3+H=382.4; found 382.1.
A solution of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid (137 mg, 0.38 mmol) in anhydrous dioxane (10 mL) was treated as described in example 10A, to give 170 mg of crude product. The residue was purified by flash chromatography, eluting with 3% MeOH in DCM then 93:6:1 DCM/MeOH/NH4OH. The product was isolated as an off white solid (61 mg, 32.6%). H1-NMR (CDCl3): δ 8.59 (m, 2H), 8.31 (s, 1H) 7.23 (s, 1H), 6.73 (m, 1H) 6.44 (s, 1H) 6.38 (m, 2H), 4.91 (m, 2H), 4.62 (s, 2H), 3.91, 3.76 (s, 3H each), 1.51 (s, 9H), 1.30 (t, 3H, J=6.9 Hz) [Note: Rotamers are observed.]; MS: APCI (M+H) calc'd for C26H33N5O5+H 496.6; found 496.1.
A solution of [4-(3-ethyl-3-pyridin-4-ylmethyl-ureido)-6,8-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert butyl ester (61 mg, 0.12 mmol) in 2 mL of EtOAc was treated as described in example 10, to give 44 mg (65%) of the desired amine hydrochloride. MS: APCI (M+H) calc'd for C21H25N5O3+H 396.5; found 396.1
A solution of 1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinoline-4-carboxylic acid (673 mg, 1.86 mmol) and diisopropylethylamine (288 mg, 2.23 mmol) in DMF (20 mL) was treated with diphenyl phosphoryl azide (562 mg, 2.04 mmol) dropwise at room temperature. After stirring at room temperature for 2 h, water (2.5 mL) was added and the reaction mixture was heated at 100° C. for 16 h. After cooling, the mixture was diluted with a 1.0% solution of NH4OH in 1.0 N NaOH (50 mL) and extracted with EtOAc (3×). The combined organic layers were washed with water (4×), brine (1×), dried (Na2SO4), and concentrated. The residue was diluted with in 125 mL of EtOAc. The resulting suspension was filtered, and 227 mg of product was isolated as a light brown solid. The filtrate was diluted with 3 mL of HCl (1.0 N in diethyl ether) and the resulting HCl salt was collected by filtration and then taken up in 1.0 N NaOH and extracted with CH2Cl2 (3×30 mL). The combined organic layers were dried and concentrated to give a 251 mg of additional product. The combined yield of (4-amino-6,8-dimethoxy-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester was 478 mg (77%). 1H-NMR (CDCl3): δ, 7.90 (s, 1H), 6.74 (s, 1H), 6.60 (d, 1H, J=2.1 Hz), 6.56 (d, 1H, J=1.9 Hz), 4.95 (d, 2H, J=4.5 Hz), 3.95 (s, 6H), 3.78 (s, 2H), 1.51 (s, 9H), 1.40 (t, 3H, J=7.3 Hz); MS: calculated for C17H23N3O4+H 334.0; found: 334.0.
(4-Amino-6,8-dimethoxy-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (225 mg, 0.675 mmol) was taken up in 10 mL of dry acetone, and benzoylisothiocyanate (121 mg, 0.742 mmol) was added dropwise. The reaction was stirred at room temperature for 2 h, and was then concentrated to a yellow solid. This solid was triturated with 50% aqueous EtOH, filtered, and suspended in 10% NaOH (5.0 mL). The reaction mixture was placed in an oil bath that was pre-heated to 98° C. for 1 h, (the solid was dissolved in 10 min). The mixture was cooled, acidified to pH 6-7 by 2.0 N aqueous HCl solution, and filtered. The yellow solid was washed with water, and dried in vacuo to give 126 mg (48%) of (6,8-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester. 1H-NMR (CDCl3): δ, 8.34 (s, 1H), 7.60 (s, 1H), 6.78 (d, 1H, J=2.1 Hz), 6.63 (d, 1H, J=1.9 Hz), 5.06 (d, 2H, J=3.7 Hz), 4.00 (s, 3H), 3.96 (s, 3H), 3.65 (s, 2H), 1.51 (s, 9H); MS: calculated for C18H24N4O4S+H 393.0; found: 393.0.
To solution of (6,8-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (50 mg, 0.127 mmol) and chloroacetone (16.1 mg, 0.166 mmol) in acetone (1.4 mL) was added MgSO4 (7.7 mg, 0.0637 mmol). The resulting suspension was stirred at 60° C. and for 4.5 h. The reaction was cooled and concentrated. The residue passed through a 5 g silica cartridge, eluting with 2% MeOH in DCM, to give [6,8-dimethoxy-4-(4-methyl-thiazol-2-ylamino)isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester as a yellow solid (21.3 mg; 39%). 1H-NMR (CDCl3): δ, 8.59 (s, 1H), 7.00 (s, 1H), 6.76 (s, 1H), 6.61 (d, 1H, J=2.2 Hz), 6.13 (s, 1H), 5.05 (d, 2H, J=4.3 Hz), 3.99 (s, 3H), 3.92 (s, 3H), 2.32 (s, 3H), 1.51 (s, 9H); MS: calculated for C21H26N4O4S+H 431.0; found: 431.0.
To a solution of [6,8-dimethoxy-4-(4-methyl-thiazol-2-ylamino)-isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester (20 mg, 0.045 mmol) in 1 mL CH2Cl2 was added a 4.0 M HCl solution in dioxane (0.70 mL). After the reaction mixture was stirred at room temperature for 20 h, the resulting yellow solid was collected by suction filtration, and dried in vacuo to give (1-aminomethyl-6,8-dimethoxy-isoquinolin-4-yl)-(4-methyl-thiazol-2-yl)amine hydrochloride salt (9.0 mg, 53%). 1H-NMR (D2O): δ, 8.35 (s, 1H), 6.75 (s, 2H), 6.35 (s, 1H), 4.78 (s, 2H), 3.89 (s, 3H), 3.77 (s, 3H), 2.06 (s, 3H); MS: calculated for C16H19N4O2S (M−Cl) 331.0; found: 331.0.
To a solution of (6,8-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (62 mg, 0.158 mmol) and ethyl bromopyruvate (37.7 mg, 0.174 mmol) in acetone (1.6 mL) was added MgSO4 (9.5 mg, 0.079 mmol). The resulting suspension was stirred at 60° C. for 3 h. The reaction was cooled to RT and concentrated. The residue was purified by passing through a 5 g silica cartridge eluting with 2% MeOH in DCM to give 2-[1-(tert-butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinolin-4-ylamino]thiazole-4-carboxylic acid ethyl ester as a pale yellow solid (32.5 mg, 42%). 1H-NMR (CDCl3): δ, 8.53 (s, 1H), 7.47 (s, 1H), 6.82 (s, 1H), 6.61 (s, 1H), 5.07 (d, 2H, J=4.2 Hz), 4.41 (q, 2H, J=7.2 Hz), 4.00 (s, 3H), 3.89 (s, 3H), 1.52 (s, 9H), 1.41 (t, 3H, J=7.3 Hz); MS: calculated for C23H28N4O6S+H 489.0; found: 489.0.
2-[1-(tert-Butoxycarbonylamino-methyl)-6,8-dimethoxy-isoquinolin-4-ylamino]thiazole-4-carboxylic acid ethyl ester (22 mg, 0.045 mmol) in CH2Cl2 (1.0 mL) was added a 4.0 M HCl solution in dioxane (0.67 mL) at room temp. After the reaction mixture was stirred at room temperature for 4.5 h, the suspension was filtered. The yellow solid was dried in vacuo to give 2-(1-aminomethyl-6,8-dimethoxy-isoquinolin-4-ylamino)thiazole-4-carboxylic acid ethyl ester hydrochloride salt (14.0 mg; 73% yield). 1H-NMR (D2O): δ, 8.84 (d, 1H, J=6.3 Hz), 7.70 (s, 1H), 6.92 (s, 1H), 6.77 (s, 1H), 4.66 (s, 2H), 4.20 (q, 2H, J=7.1 Hz), 3.92 (s, 3H), 3.84 (s, 3H), 1.20 (t, 3H, J=7.3 Hz); MS: calculated for C18H21N4O4S (M−Cl) 389.0; found: 389.0.
To a solution of (6,8-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (50 mg, 0.127 mmol) and 2-chloro-cyclohexanone (23.1 mg, 0.166 mmol) in acetone (1.4 mL) was added MgSO4 (7.7 mg, 0.0637 mmol). The resulting suspension was stirred at 60° C. for 20 h. The reaction was cooled and concentrated. The residue was purified by preparative TLC (MeOH/CH2Cl2, 5:95) to give [6,8-dimethoxy-4-(4,5,6,7-tetrahydro-benzothiazol-2-ylamino)isoqunilin-1-ylmethyl]carbamic acid tert-butyl ester as a yellow solid (3.3 mg; 6% yield). MS: calculated for C24H30N4O4S+H 471.0; found: 471.1.
[6,8-Dimethoxy-4-(4,5,6,7-tetrahydro-benzothiazol-2-ylamino)isoqunilin-1-ylmethyl]carbamic acid tert-butyl ester (3.3 mg, 0.0070 mmol) in CH2Cl2 (0.5 mL) was added a 4.0 M HCl solution in dioxane (0.50 mL) at room temp. After the reaction mixture was stirred at room temperature for 15 h, the resulting yellow solid was collected by filtration and dried in vacuo to yield (1-aminomethyl-6,8-dimethoxy-isoquinolin-4-yl)-(4,5,6,7-tetrahydro-benzothiazol-2-yl)amino hydrochloride salt (0.5 mg; 18%). MS: calculated for C19H23N4O2S (M−Cl) 371.0; found: 371.0.
A solution of 1-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester1 (995 mg, 2.37 mmol) in ethanol was treated with hydrazine monohydrate (1.30 g, 26.0 mmol), as described in Example 1B above, to give 724 g of crude amine, which was used without further purification. H1-NMR (DMSO): δ 8.84 (s, 1H), 8.24 (s, 1H), 7.50 (s, 1H), 4.37 (q, 2H, J=7.1 Hz), 4.28 (s, 2H), 3.94 and 3.91 (s, 3H each), 1.36 (t, 3H, J=6.9 Hz).
A solution of crude 1-aminomethyl-6,7-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester (724 mg, 2.49 mmol) in 30 mL THF was treated with Boc anhydride (650 mg, 2.98 mmol) and TEA (716 mg, 7.08 mmol) as describe in Example 1C to give 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester (974 mg, 83.4%). H1-NMR (CDCl3): δ 9.01 (s, 1H), 8.50 (s, 1H), 7.36 (s, 1H), 6.27 (m, 1H), 4.92 (d, J=4.4 Hz, 2H), 4.47 (q, J=6.9 Hz, 2H), 4.08 and 4.04 (s, 3H each), 1.51 (s, 9H), 1.47 (t, J=7.2 Hz, 3H).
A sample of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid ethyl ester was hydrolyzed with 2 eq of LiOH as described in Example 1D to give 1-(tert-Butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid: 1H NMR (DMSO-d6) δ 1.37 (s, 9H), 3.90 (s, 3H), 3.93 (s, 3H), 4.74 (d, 2H), 7.33-7.36 (m, 1H), 7.61 (s, 1H), 8.37 (s, 1H), 8.82 (s, 1H).
A solution of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (100 mg, 0.3 mmol) in 20 mL of THF was treated with 1,2,3,4-tetrahydroisoquinoline (44 mg, 0.33 mmol), TEA (56 mg, 0.552 mmol) and diethyl cyanophosphonate (55 mg, 0.33 mmol) according to the procedure described in example 1E to give [4-(3,4-Dihydro-1H-isoquinoline-2-carbonyl)-6,7-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (88 mg, 66.9%). H1-NMR (CDCl3): δ, 8.31 (br s, 1H), 7.38 (br s, 1H), 7.15 (m, 5H), 6.82 (m, 1H), 6.18 (br s, 1H), 4.93 (s, 2H), 4.43 (m, 2H), 4.02 (br s, 3H), 3.92 (s, 2H), 3.58 (br s, 3H), 3.10 (br s, 1H), 2.80 (br s, 1H), 1.51 (s, 9H) [Note: broadening of peaks observed due to Boc group, rotamers also observed.]; MS: APCI (M+H) calc'd for C27H31N3O5+H 478.6; found 478.0.
A solution of [4-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-6,7-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (81 mg, 0.17 mmol) in 2 mL EtOAc was treated with HCl (6N in dioxane) according to Example 1 to give (1-Aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone as the hydrochloride salt (77 mg, 93%). MS: APCI (M+H) calc'd for C22H23N3O3+H 378.4; found 378.1.
Step A: As described in example 1E, 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (80 mg, 0.22 mmol), diethylphosphoryl cyanide (54 mg, 0.33 mmol), and 2-methoxy ethylamine (25 mg, 0.33 mmol) were reacted to give [6,7-dimethoxy-4-(2-methoxy-ethylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (45 mg, 49%): 1H NMR (CDCl3) δ 1.50 (s, 9H), 3.41 (s, 3H), 3.62-3.64 (m, 2H), 3.72-3.76 (m, 2H), 4.03 (s, 6H), 4.89 (d, 2H), 6.19 (s, 1H), 6.47 (s, 1H), 7.34 (s, 1H), 7.85 (s, 1H), 8.47 (s, 1H); MS (APCI) m/z 419.9 [M+1]+.
Step B: A solution of [6,7-dimethoxy-4-(2-methoxy-ethylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (45 mg, 0.11 mmol) in dioxane (2 ml) was treated with 4M HCl in dioxane (2 ml) and the mixture was stirred overnight at room temperature. Diethyl ether was added and the HCl salt was collected by suction filtration (38 mg, quant.): 1H NMR (DMSO-d6) δ 3.28 (s, 3H), 3.47-3.53 (m, 4H), 3.89 (s, 3H), 3.99 (s, 3H), 4.72 (m, 2H), 7.46 (s, 1H), 7.70 (s, 1H), 8.42 (s, 1H), 8.65 (br s, 3H), 8.82 (m, 1H); MS (APCI) m/z 320.1 [M+1]+.
Step A: As described in example 1E, 80 mgs of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid was coupled with 4-methoxybenzylamine to give 84 mgs (79%) of [6,7-Dimethoxy-4-(4-methoxy-benzylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester: 1H NMR (CDCl3) δ 1.50 (s, 9H), 2.78 (s, 2H), 3.18 (s, 1H), 3.77 (s, 2H), 4.02 (d, 4H, J=7.17 Hz), 4.15-4.33 (m, 1H), 4.42 (s, 1H), 4.87-4.90 (m, 1H), 6.10-6.22 (m, 1H), 6.93 (s, 0.6H), 7.06-7.12 (m, 1H), 7.16 (s, 0.4H), 7.27-7.42 (m, 4H), 7.50 (d, 1H, J=7.60 Hz), 8.32 (d, 1H, J=7.19 Hz); MS: APCI (M+H) calc'd for C26H31N3O6 482.2; found 482.0.
Step B: As described in example 1, a solution of [6,7-dimethoxy-4-(4-methoxy-benzylcarbamoyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (84 mg) was treated with HCl in EtOAc to give 46 mg (69%) of 1-aminomethyl-6,7-dimethoxy-isoquinoline-4-carboxylic acid 4-methoxy-benzylamide hydrochloride: 1H NMR (DMSO-d6) δ 3.71 (s, 3H), 3.80 (s, 3H), 3.98 (s, 3H), 4.45 (d, 2H, J=6.03 Hz), 4.69-4.72 (m, 2H), 6.90 (d, 211, J=8.64 Hz), 7.32 (d, 2H, J=8.53 Hz), 7.44 (s, 1H), 7.61 (s, 1H), 8.46 (s, 1H), 8.59-8.62 (br s, 3H), 9.25 (t, 1H, J=6.53 Hz); MS: APCI (M−H) calc'd for C21H23N3O4 380.2; found 380.0.
Step A: As described in example 1E, 80 mgs of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid was coupled with N-methylbenzylamine to give 82 mgs (8%) of [4-(benzyl-methyl-carbamoyl)-6,7-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester: 1H NMR (CDCl3) δ 1.50 (s, 9H), 3.77 (s, 3H), 4.02 and 4.03 (2s, 6H), 4.87-4.90 (m, 4H), 6.10-6.22 (m, 1H), 6.93 (s, 0.6H), 7.06-7.12 (m, 1H), 7.16 (s, 0.4H), 7.27-7.42 (m, 4H), 7.50 (d, 1H, J=7.60 Hz), 8.32 (s, 1H).
Step B: As described in example 1, a solution of [4-(benzyl-methyl-carbamoyl)-6,7-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (82 mg) was treated with HCl in EtOAc to give 56 mg (79%) of 1-aminomethyl-6,7-dimethoxy-isoquinoline-4-carboxylic acid benzyl-methyl-amide hydrochloride: 1H NMR (DMSO-d6) δ 2.68 (s, 2H), 3.67 (s, 2H), 3.91 (s, 1H), 3.97 (s, 3H), 4.33 (br s, 1H), 4.67-4.72 (m, 3H), 6.80 (s, 1H), 7.04-7.51 (m, 6H), 8.36 (d, 1H, J=4.26 Hz), 8.56-8.63 (m, 3H); MS: APCI (M+H) calc'd for C21H23N3O3 366.2; found 366.1.
Step A: As described in example 1E, 100 mgs of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid was coupled with pyrrolidine to give 74 mgs (64%) of [6,7-dimethoxy-4-(pyrrolidine-1-carbonyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester: 1H NMR (CDCl3) δ 1.51 (s, 9H), 1.83-1.92 (m, 2H), 2.02-2.07 (m, 2H), 3.20-3.29 (m, 2H), 4.03 (m, 6H), 4.92 (br s, 2H), 6.17 (br s, 2H), 7.23-7.24 (m, 1H), 7.38 (br s, 1H), 8.31-8.33 (m, 1H).
Step B: As described in example 1, a solution of [6,7-dimethoxy-4-(pyrrolidine-1-carbonyl)-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester (59 mg) was treated with HCl in EtOAc to give 42 mg (84%) of (1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-pyrrolidin-1-yl-methanone hydrochloride: 1H NMR (DMSO-d6) δ 1.74-1.81 (m, 2H), 1.86-1.92 (m, 2H), 3.10 (t, 2H, J=6.41 Hz), 3.59 (t, 2H, J=6.50 Hz), 3.89 (s, 3H), 3.99 (s, 3H), 4.71 (m, 2H), 7.09 (s, 1H), 7.49 (s, 1H), 8.36 (s, 1H), 8.68 (br s, 3H); MS: APCI (M+H) calc'd for C17H21N3O3 316.2; found 316.1.
In a 100 mL round bottom flask 1A in 35 mL THF (0.1M) was treated with diisopropylethylamine at room temperature and stirred until the solid dissolved. The solution was then cooled to 0° C., and diphenylphosphoryl azide was added dropwise. The reaction was then allowed to stir with warming to room temperature overnight. One half of the solvent was removed in vacuo and was replaced with ether. It was then cooled to 0° C. and was washed with ice-cold aqueous sodium bicarbonate, then cold brine. The solution was dried quickly over MgSO4, and filtered through a 1 cm plug of SiO2. Concentration in vacuo gave a light yellow solid, which was used directly in the next step. H1-NMR (CDCl3): δ 9.04 (s, 1H), 8.59 (s, 1H), 7.38 (s, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 1.52 (s, 9H).
Method A: A solution of 1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid in 3 mL of toluene and 3 mL of dioxane at room temperature was treated with diisopropylethyl amine and stirred until the solids dissolved. Diphenylphosphoryl azide was added dropwise and the reaction was heated to 95° C. After 30 min, the reaction was removed from the heating bath, and N-methyl, N-benzyl amine was added. The reaction was then heated at 75° C. for 4 h. After cooling to room temperature, the solution was diluted with 20 mL of EtOAc and washed successively with 10 mL water, 10 mL of 1% NH4OH, and 10 mL of brine. The organic phase was dried over MgSO4, and filtered though a 1-cm plug of silica. After evaporation of the solvent, the residue was purified by flash chromatography, on a 5 g silica cartridge, eluting with 3% MeOH in DCM.
Method B: A solution of (4-Azidocarbonyl-6,7-dimethoxy-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester (170 mg, 0.439 mmol) in 10 mL toluene under a nitrogen atmosphere, was heated to 95° C. for 30 min. The reaction vessel was then removed from the oil bath, and allowed to cool for several minutes before adding N-methyl N-benzylamine. The resulting mixture was then stirred at 75-80° C. for 6 h. After cooling to room temperature, the reaction was diluted with 25 mL EtOAc, and washed with 10 mL of 5% NH4OH. The organic phase was removed, and the aqueous phase was extracted with EtOAc (2×15 mL). The combined organics were washed with brine, dried over MgSO4, filtered through a short plug of silica and concentrated. The residue was purified as in method A to give 122 mg (58%) of pure product. H1-NMR (CDCl3): δ 8.30 (s, 1H), 7.3-7.4 (m, 5H), 7.29 (s, 1H), 6.77 (s, 1H), 6.35 (s, 1H), 6.12 (s, 1H), 4.81 (d, J=4.7 Hz, 2H), 4.66 (s, 2H), 3.99 (s, 3H), 3.81 (s, 3H), 3.17 (s, 3H), 1.49 (s, 9H). MS: APCI (M+H) calc'd for C26H32N4O5+H 481.6; found 481.0.
A solution of the Boc protected amine, [4-(3-benzyl-3-methyl-ureido)-6,7-dimethoxy-isoquinolin-1-ylmethyl]-carbamic acid tert-butyl ester, (155 mg) was taken up in 5 mL of EtOAc, then 600 μL of HCl in EtOAc was added and the reaction was allowed to stir overnight. Solvent was removed in vacuo, and the resulting white solid was washed with ether to give 109 mg (89%) of the desired product as the hydrochloride salt. H1-NMR (CDCl3): δ 8.31 (s, 1H), 7.3-7.4 (m, 5H), 7.17 (s, 1H), 6.82 (s, 1H), 6.51 (s, 1H), 4.66 (s, 2H), 4.29 (s, 2H), 3.99 (s, 3H), 3.83 (s, 3H), 3.16 (s, 3H), 2.83 (br s, 1H). MS: APCI (M+H) calc'd for C26H32N4O5+H 481.6; found 481.0.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C18H25N5O3+H 360.5; found 360.0
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C17H22N4O4+H 347.5; found 347.1.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C21H29N5O5+H 432.5; found 432.1.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C19H27N5O3+H 374.6; found 374.0.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C23H27N5O3+H 422.6; found 422.1.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C21H25N5O3+H 396.6; found 396.1.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C20H23N5O3+H 382.5; found 382.1.
The HCl salt was prepared according to the two-step procedure described above, applying method B. MS: APCI (M+H) calc'd for C22H26N4O4+H 411.6; found 411.1.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C18H27N5O3+H 362.5; found 362.8.
The HCl salt was prepared according to the two-step procedure described in Example 22 above, applying method B. MS: APCI (M+H) calc'd for C22H26N4O3+H 395.6; found 395.1.
A solution of (4-Azidocarbonyl-6,7-dimethoxy-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester (1.36 g) in 40 mL of toluene was heated to 95° C. for 20 min, then the reaction flask was removed from the oil bath and benzyl alcohol (600 mg, 1.5 eq) and triethylamine (355 mg, 1.0 eq) were added. The reaction was allowed to stir at 80° C. After 3 h, TLC indicated clean conversion to a single product. The reaction was diluted with 30 mL EtOAc, and 25 mL 1% NH4OH. The aqueous phase was extracted with 20 mL EtOAc, and the combined organics were washed with brine, dried over MgSO4, and filtered though a 1-cm plug of silica. After removal of the solvent, the residue was purified by flash chromatography, eluting with a gradient of 1%-5% MeOH in DCM to give 1.05 g (64%) of the desired product. H1-NMR (CDCl3): δ 8.50 (br s, 1H), 7.3-7.5 (m, 1H), 6.75 (s, 1H), 6.12 (s, 1H), 5.24 (s, 2H), 4.82 (d, 1H), 4.00 (s, 3H), 3.91 (s, 3H), 1.49 (s, 9H).
A solution of [1-(tert-Butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-carbamic acid benzyl ester, in 45 mL of EtOH and 20 mL THF was hydrogenated at 1 atm (balloon) over 60 mg of 10% Pd—C for 3 h. The catalyst was removed by filtration through a plug of celite and the filtrate was concentrated to give a white film. Trituration with ether gave 534 mg (89%) of the 4-aminoisoquinoline as a white granular solid. H1-NMR (CDCl3): δ 7.84 (s, 1H), 7.36 (s, 1H), 7.02 (s, 1H), 6.00 (s, 1H), 4.78 (d, J=5.1 Hz, 1H), 4.03 (s, 3H), 4.01 (s, 3H), (s, 1H), 3.89 (s, 2H), 1.48 (s, 9H). MS: APCI (M+H) calc' d for C18H24N2O4+H 334.4; found 334.0.
(4-Amino-6,7-dimethoxy-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (277 mg, 0.831 mmol) was dissolved in dry acetone, and benzoylisothiocyanate (149 mg, 0.914 mmol) was added dropwise. The reaction was stirred at room temperature for 2 h, and was concentrated to yield a yellow solid. This solid was triturated with 50% aqueous EtOH, filtered, and suspended in 10% NaOH (5.0 mL). The reaction mixture was placed in an oil bath that was pre-heated to 98° C. for 1 h, (the solid was dissolved in 10 min). The mixture was cooled and filtered. The yellow solid was washed with water, and dried in vacuo to give (6,7-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (165 mg; 51%). 1H-NMR (CDCl3): δ, 8.31 (s, 1H), 7.66 (s, 1H), 7.38 (s, 1H), 4.81 (s, 2H), 4.05 (s, 3H), 4.00 (s, 3H), 2.81 (s, 2H), 1.46 (s, 9H); MS: calculated for C18H24N4O4S+H 393.0; found: 392.9.
A solution of (6,7-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (50 mg, 0.127 mmol) and 2-bromoacetophenone (27.9 mg, 0.140 mmol) in acetone (1.4 mL) in a conical vial was added MgSO4 (7.7 mg, 0.0637 mmol). The resulting suspension was placed in an aluminum block preheated to 60° C. and was allowed to stir for 3.0 h. The reaction was cooled and concentrated. The residue was purified using a 5.0 g silica cartridge (MeOH/CH2Cl2, 1:99) to give [6,7-dimethoxy-4-(4-phenyl-thiazol-2-ylamino)isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester as a yellow solid (44.6 mg; 71%). 1H-NMR (CDCl3): δ, 8.64 (s, 1H), 7.52-7.41 (m, 6H), 6.76 (s, 1H), 6.17 (s, 1H), 4.92 (d, 2H, J=4.7 Hz), 4.06 (s, 3H), 4.02 (s, 3H), 1.51 (s, 9H); MS: calculated for C26H28N4O4S+H 493.5; found: 493.5.
[6,7-Dimethoxy-4-(4-phenyl-thiazol-2-ylamino)isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester (44 mg, 0.0853 mmol) in CH2Cl2 (1 mL) was added a 4.0 M HCl solution in dioxane (0.21 mL) at room temp. After the reaction mixture was stirred at room temperature for 21 h, the suspension was filtered. The yellow solid was further dried in vacuo to give (1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-(4-phenyl-thiazol-2-yl)amine hydrochloride salt (26.1 mg; 71%). 1H-NMR (D2O): δ, 8.82 (s, 1H), 7.09-7.00 (m, 6H), 6.69 (s, 1H), 6.51 (s, 1H), 4.43 (s, 2H), 3.70 (s, 3H), 3.59 (s, 3H); MS: calculated for C21H21N4O2S (M−Cl) 393.0; found: 393.0.
A solution of (6,7-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (50 mg, 0.127 mmol) and chloroacetone (13.0 mg, 0.140 mmol) in acetone (1.4 mL) in a conical vial was added MgSO4 (7.7 mg, 0.0637 mmol). The resulting suspension was placed in an aluminum block preheated to 60° C. and was allowed to stir for 20 h. The reaction was cooled and concentrated. The residue was purified using a 5 g silica cartridge (MeOH/CH2Cl2, 2:98) to give [6,7-dimethoxy-4-(4-methyl-thiazol-2-ylamino)isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester as a yellow solid (17.4 mg; 32%). MS: calculated for C21H26N4O4S+H 431.0; found: 431.0.
[6,7-Dimethoxy-4-(4-methyl-thiazol-2-ylamino)-isoquinolin-1-ylmethyl]carbamic acid tert-butyl ester (11.6 mg, 0.0269 mmol) in CH2Cl2 (0.6 mL) was added a 4.0 M HCl solution in dioxane (0.40 mL) at room temp. After the reaction mixture was stirred at room temperature for 5.0 h, the suspension was filtered. The yellow solid was further dried in vacuo to give (1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-(4-methyl-thiazol-2-yl)amine hydrochloride salt (7.4 mg; 75%). 1H-NMR (D2O): δ, 8.33 (s, 1H), 7.26 (s, 1H), 7.15 (s, 1H), 6.34 (s, 1H), 4.70 (s, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 2.05 (s, 3H); MS: calculated for C16H19N4O2S (M−Cl) 331.0; found: 331.0.
A solution of (6,7-dimethoxy-4-thioureido-isoquinolin-1-ylmethyl)carbamic acid tert-butyl ester (50 mg, 0.127 mmol) and ethyl bromopyruvate (30.4 mg, 0.140 mmol) in acetone (1.4 mL) in a conical vial was added MgSO4 (7.7 mg, 0.0637 mmol). The resulting suspension was placed in an aluminum block preheated to 60° C. and was allowed to stir for 3.0 h. The reaction was cooled and concentrated. The residue was purified using a 5 g silica cartridge (MeOH/CH2Cl2, 1:99) to give 2-[1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-ylamino]thiazole-4-carboxylic acid ethyl ester as a pale yellow solid (42.2 mg; 68%). 1H-NMR (CDCl3): δ, 8.51 (s, 1H), 7.48 (s, 1H), 7.42 (s, 1H), 6.13 (s, 1H), 4.91 (d, 2H, J=4.7 Hz), 4.39 (q, 2H, J=7.0 Hz), 4.05 (s, 3H), 3.99 (s, 3H), 1.50 (s, 9H), 1.40 (t, 3H, J=7.3 Hz); MS: calculated for C23H28N4O6S+H 489.0; found: 489.0.
2-[1-(tert-Butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-ylamino]-thiazole-4-carboxylic acid ethyl ester (40 mg, 0.0818 mmol) in CH2Cl2 (1.0 mL) was treated with a 4.0 M HCl solution in dioxane (0.21 mL) at room temperature. After the reaction mixture was stirred at room temperature for 15 h, the suspension was filtered. The yellow solid was dried in vacuo to give 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-ylamino)thiazole-4-carboxylic acid ethyl ester hydrochloride salt (32.3 mg; 93%). 1H-NMR (D2O): δ, 8.81 (s, 1H), 7.46 (s, 1H), 7.18 (s, 1H), 7.13 (s, 1H), 4.63 (s, 2H), 4.14 (q, 2H, J=7.1 Hz), 3.86 (s, 3H), 3.83 (s, 3H), 1.20 (t, 3H, J=7.3 Hz); MS: calculated for C18H21N4O4S (M−Cl) 389.0; found: 389.0.
[1-(tert-Butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid ethyl ester (338 mg, 0.83 mmol) was hydrolysed with LiOH—H2O (60 mg, 1.4 mmol) according to the procedure outlined in example 1D to give [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid (265 mg, 84%). H1-NMR (DMSO): δ 8.11 (s, 1H), 7.57 (s, 1H), 7.28 (t, 3H, J=5.9 Hz), 7.24 (s, 1H), 4.67 (d, 2H), 3.93 (s, 2H), 3.90 and 3.88 (s, 3H each), 1.37 (s, 9H); MS: APCI (M+H) calc'd for C19H24N2O6+H 377.4; found 377.0.
[1-(tert-Butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid (70 mg, 0.19 mmol) was treated with 4-methoxybenzylamine (31 mg, 0.22 mmol), diethyl cyanophosphonate (36 mg, 0.22 mmol), and TEA (38 mg, 0.37 mmol) according to the procedure described in example 1E to give {6,7-dimethoxy-4-[(4-methoxy-benzylcarbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester (74 mg, 80.7%). H1-NMR (CDCl3): 8.19 (s, 1H), 7.37 (s, 1H), 7.18 (s, 1H), 6.97 (d, 2H, J=8.8 Hz), 6.73 (d, 2H, J=8.5 Hz), 6.14 (m, 1H), 5.62 (m, 1H), 4.87 (d, 2H, J=4.3 Hz), 4.26 (d, 2H, J=6.0 Hz), 4.03 (s, 2H), 3.94, 3.91, and 3.75 (s, 3H each), 1.50 (s, 9H); MS: APCI (M+H) calc'd for C27H33N3O6+H 496.6; found 496.0.
To a solution of {6,7-dimethoxy-4-[(4-methoxy-benzylcarbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester (64 mg, 0.13 mmol) in 1.5 mL of EtOAc was added 3 mL of a 4 M solution of HCl in dioxane. After stirring at room temperature for 1 h, 1 mL of EtOH was added to facilitate solution. The reaction was stirred for 48 hours and the precipitated HCl salt was collected by filtration (58 mg, >100%). H1-NMR (DMSO): 9.00 (m, 1H), 8.79 (br s, 3H), 8.35 (s, 1H), 7.62 (s, 1H), 7.46 (s, 1H), 7.12 (d, J=8.5 Hz, 2H), 6.80 (d, 2H, J=8.3 Hz), 4.75 (br s, 2H), 4.18 (d, J=5.4 Hz, 2H), 4.02 (s, 3H), 4.00 (s, 2H), 3.82 and 3.68 (s, 3H); MS: APCI (M+H) calc'd for C22H25N3O4+H 396.5; found 396.2.
Step A: As described in Example 1, 83 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with benzyl-methyl-amine to give 69 mg of {4-[(benzyl-methyl-carbamoyl)-methyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C27H33N3O5+H 480.6; found 480.0.
Step B: As described in Example 1, 60 mg of {4-[(benzyl-methyl-carbamoyl)-methyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 31 mg (66%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-benzyl-N-methyl-acetamide hydrochloride. MS: APCI (M+H) calc'd for C22H25N3O3+H 380.5; found 380.1.
Step A: As described in Example 1, 60 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with 2-methoxy-ethylamine to give 40 mg of {6,7-dimethoxy-4-[(2-methoxy-ethylcarbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. H1-NMR (CDCl3): δ, d 8.21 (s, 1H), 7.40 (s, 1H), 7.25 (s, 1H), 6.17 (br s, 1H), 5.74 (br s, 1H), 4.89 (d, J=4.7 Hz, 2H), 4.03 (s, 6H), 3.89 (s, 2H), 3.36 (m, 4H), 3.17 (s, 3H), 1.51 (s, 9H); MS: APCI (M+H) calc'd for C22H31N3O6+H 434.5; found 434.0.
Step B: As described in Example 1, 37 mg of {6,7-dimethoxy-4-[(2-methoxy-ethylcarbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 40 mg (>100%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-(2-methoxy-ethyl)-acetamide hydrochloride. MS: APCI (M+H) calc'd for C17H23N3O4+H 334.3; found 334.1.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with 1,2,3,4-tetrahydro-isoquinoline to give 94 mg of {4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C28H33N3O5+H 492.6; found 492.0.
Step B: As described in Example 1, 84 mg of {4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 74 mg (99%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-ethanone hydrochloride. MS: APCI (M+H) calc'd for C23H25N3O3+H 392.5; found 392.1.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with methyl-(1-phenyl-ethyl)-amine to give 85 mg of (6,7-dimethoxy-4-{[methyl-(1-phenyl-ethyl)-carbamoyl]-methyl}-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C28H35N3O5+H 494.6; found 494.1.
Step B: As described in Example 1, 85 mg of (6,7-dimethoxy-4-{[methyl-(1-phenyl-ethyl)-carbamoyl]-methyl}-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 67 mg (99%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-methyl-N-(1-phenyl-ethyl)-acetamide hydrochloride. MS: APCI (M+H) calc'd for C23H27N3O3+H 394.5; found 394.1.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with methyl-pyridin-3-ylmethyl-amine to give {6,7-dimethoxy-4-[(methyl-pyridin-3-ylmethyl-carbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C26H32N4O5+H 481.6; found 481.0.
Step B: As described in Example 1, {6,7-dimethoxy-4-[(methyl-pyridin-3-ylmethyl-carbamoyl)-methyl]-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-methyl-N-pyridin-3-ylmethyl-acetamide hydrochloride. MS: APCI (M+H) calc'd for C21H24N4O3+H 381.4; found 381.1.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with benzyl-ethyl-amine to give 84 mg of {4-[(Benzyl-ethyl-carbamoyl)-methyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C28H35N3O5+H 494.6; found 494.1.
Step B: As described in Example 1, 84 mg of {4-[(benzyl-ethyl-carbamoyl)-methyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 64 mg (95%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-benzyl-N-ethyl-acetamide hydrochloride. MS: APCI (M+H) calc'd for C23H27N3O3+H 394.5; found 394.2.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with methyl-(2-pyridin-2-yl-ethyl)-amine to give 78 mg of (6,7-dimethoxy-4-{[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-methyl}-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C27H34N4O5+H 495.6; found 495.1.
Step B: As described in Example 1, 78 mg of (6,7-dimethoxy-4-{[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-methyl}-isoquinolin-1-ylmethyl)-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 86 mg (>100%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-N-methyl-N-(2-pyridin-2-yl-ethyl)-acetamide hydrochloride. MS: APCI (M+H) calc'd for C22H26N4O3+H 395.5; found 395.1.
Step A: As described in Example 1, 94 mg of [1-(tert-butoxycarbonylamino-methyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid was coupled with 4-benzyl-piperidine to give 132 mg of {-4-[2-(4-benzyl-piperidin-1-yl)-2-oxo-ethyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester. MS: APCI (M+H) calc'd for C31H39N3O5+H 534.7; found 534.1.
Step B: As described in Example 1, 94 mg of {4-[2-(4-benzyl-piperidin-1-yl)-2-oxo-ethyl]-6,7-dimethoxy-isoquinolin-1-ylmethyl}-carbamic acid tert-butyl ester was treated with HCl in EtOAc to give 114 mg (>100%) of 2-(1-aminomethyl-6,7-dimethoxy-isoquinolin-4-yl)-1-(4-benzyl-piperidin-1-yl)-ethanone hydrochloride. MS: APCI (M+H) calc'd for C26H31N3O3+H 434.5; found 434.2.
Lithium hydroxide (1N, 100 mL) was added to a solution of Example 1A (19.6 g, 46.6 mmol) in THF (50 mL), and the reaction was stirred for 16 h. The solution was acidified to pH=3 with 1N HCl. The resulting solid was collected by filtration and dried under vacuum to give 12.6 g (69%) of the title compound. H1-NMR (DMSO-d6): δ 8.90 (s, 1H), 8.58 (t, 1H, J=4.8 Hz), 8.01 (d, 1H, J=2.0 Hz), 7.73 (d, 1H, J=3.6 Hz), 7.66 (d, 1H, J=3.6 Hz), 7.58 (t, 1H, J=3.6 Hz), 7.52 (t, 1H, J=3.6 Hz), 5.10 (d, 2H, J=4.8 Hz), 4.02 (s, 3H), 3.91 (s, 3H). MS (ES) (M+H) calc'd for C21H16N2O6, 393; found 393.
Example 45A (3.0 g, 7.65 mmol) was stirred in a mixture of dry toluene (50 mL) and dioxane (50 mL) at r.t. DIEA (1.47 mL, 8.42 mmol), diphenyl phosphoryl azide (1.81 mL, 8.42 mmol), and benzyl alcohol (0.95 mL, 9.2 mmol) were added, and the reaction stirred at 90° C. for 18 h. The reaction was concentrated in vacuo. The residue was dissolved in CHCl3, washed with brine, dried (MgSO4), and concentrated. Purification by silica gel chromatography (1:1 EtOAc/CHCl3) gave 1.12 g (29%) of the title compound. H1-NMR (DMSO-d6): δ 9.53 (s, 1H), 8.19 (s, 1H), 7.86-7.96 (m, 4H), 7.31-7.42 (m, 5H), 6.94 (s, 1H), 6.81 (s, 1H), 5.40 (s, 2H), 5.14 (s, 2H), 4.04 (s, 3H), 3.88 (s, 3H). MS (ES) (M+H) calc'd for C28H23N3O6, 498; found 498.
Hydrogenation of Example 45B (1.12 g, 2.25 mmol) was carried out in methanol (100 mL) with 10% Pd/C under a balloon of hydrogen for 16 h. The solution was filtered through Celite and concentrated in vacuo. Purification by silica gel chromatography (2:1 EtOAc/CHCl3) gave 575 mg (70%) of the title compound as a yellow solid. H1-NMR (CDCl3): δ 7.84-7.90 (m, 2H), 7.69-7.74 (m, 2H), 7.68 (s, 1H), 6.58 (s, 1H), 6.54 (s, 1H), 5.50 (s, 2H), 3.97 (s, 3H), 3.93 (s, 3H). MS (ES) (M+H) calc'd for C20H17N3O4, 364; found 364.
Triethylamine (46 μL, 0.33 mmol) and then thiophosgene (13 μL, 0.16 mmol) were added to a solution of Example 45C (40 mg, 0.11 mol) in dichloromethane (3 mL), and the reaction stirred for 1 h at r.t. N-benzylmethylamine (46 μL, 0.33 mmol) was added, and the reaction stirred for 1 h. Solvent was removed in vacuo, and the residue was deprotected with a solution of hydrazine (0.1 mL) in ethanol (4 mL), stirring for 1 h. Purification by Prep-HPLC gave 18 mg (39%) of the title compound (TFA salt) as a yellow solid. H1-NMR (MeOD-d4): δ 8.15 (s, 1H), 7.22-7.38 (m, 5H), 6.70 (s, 1H), 6.66 (s, 1H), 5.18 (s, 2H), 4.58 (s, 2H), 3.96 (s, 3H), 3.81 (s, 3H), 3.23 (s, 3H). MS (ES) (M+H) calc'd for C21H24N4O2S, 397; found 397.
1-Benzyl-2-chlorobenzimidazole (51 mg, 0.21 mmol), Example 45C (76 mg, 0.21 mmol), 2-dicyclohexylphosphino-2′-(N,N-dimethyl-amino)biphenyl (17 mg, 0.1 mmol), tris(dibenzylideneacetone)dipalladium(0) (10 mg, 0.011 mmol), and potassium tert-butoxide (24 mg, 0.21 mmol) were combined in toluene (5 mL) in a flask purged with nitrogen. The reaction was stirred at 108° C. for 24 h. Solvent was removed in vacuo, and the residue was deprotected by stirring with hydrazine (0.1 mL) in ethanol (4 mL) for 1 h. Purification by Prep-HPLC gave 5.6 mg (5%) of the title compound (TFA salt) as an off-white solid. H1-NMR (MeOD-d4): δ 8.59 (s, 1H), 7.56 (d, 1H, J=6.8 Hz), 7.32-7.46 (m, 9H), 6.87 (s, 1H), 6.69 (s, 1H), 5.73 (s, 2H), 4.92 (s, 2H), 4.06 (s, 3H), 3.72 (s, 3H). MS (ES) (M+H) calc'd for C26H25N5O2, 440; found 440.
Triethylamine (210 μL, 1.52 mmol) and then thiophosgene (55 μL, 0.72 mmol) were added to a solution of Example 45C (200 mg, 0.55 mol) in dichloromethane (5 mL), and the reaction stirred 1 h at r.t. Organics were washed with 0.5 N HCl and brine, dried (MgSO4), and concentrated. The residue was dissolved in DMF (5 mL). Phenylenediamine (89 mg, 0.82 mmol) was added, and the reaction stirred at 90° C. for 2 h. Mercury(II) oxide was added, and the reaction stirred for 3 h longer before it was concentrated in vacuo. Deprotection was carried out in ethanol (5 mL) with hydrazine (0.2 mL) at r.t. for 1 h. Purification by Prep-HPLC gave 145 mg (46%) of the title compound (TFA salt) as a yellow solid. H1-NMR (MeOD-d4): δ 8.61 (s, 1H), 7.38-7.42 (m, 2H), 7.30-7.34 (m, 2H), 7.23 (s, 1H); 7.02 (d, 1H, J=2.0 Hz), 6.89 (d, 1H, J=2.0 Hz), 4.92 (s, 2H), 4.01 (s, 3H), 3.91 (s, 3H). MS (ES) (M+H) calc'd for C19H19N5O2, 350; found 350.
The title compound was prepared in 49% yield using 2-aminothiophenol according to the procedure for Example 47. H1-NMR (MeOD-d4): δ 8.92 (s, 1H), 7.69 (d, 1H, J=7.6 Hz), 7.49 (d, 1H, J=7.6 Hz), 7.34 (t, 1H, J=7.6 Hz), 7.17 (t, 1H, J=7.6 Hz), 7.11 (d, 1H, J=2.0 Hz), 6.83 (d, 1H, J=2.0 Hz), 4.84 (s, 2H), 4.05 (s, 3H), 3.84 (s, 3H). MS (ES) (M+H) calc'd for C19H18N4O2S, 367; found 367.
Thiophosgene (146 μL, 1.92 mmol) was added to a solution of Example 45C (580 mg, 1.6 mmol) and DIEA (670 μL) in THF (10 mL). After stirring for 1 h, the reaction was poured over aqueous ammonia and extracted with EtOAc. Organics were dried (MgSO4) and concentrated. The resulting crude thiourea was dissolved in THF (5 mL). Bromopyruvic acid (320 mg, 1.92 mmol) was added, and the reaction stirred for 2 h. Purification by silica gel chromatography (10% MeOH/CHCl3) gave 590 mg (75%) of the title compound as a tan solid. H1-NMR (MeOD-d4): δ 9.95 (br s, 1H), 8.81 (br s, 1H), 7.87-7.96 (m, 4H), 7.60 (br s, 1H), 7.14 (s, 1H), 6.86 (s, 1H), 5.41 (s, 2H), 4.09 (s, 3H), 3.94 (s, 3H). MS (ES) (M+H) calc'd for C24H18N4O6S, 491; found 491.
Deprotection of Example 49A (40 mg, 0.081 mmol) was carried out with hydrazine (0.2 mL) in methanol (3 mL), stirring for 1 h. Purification by Prep-HPLC gave 26 mg (67%) of the title compound (TFA salt) as a yellow solid. H1-NMR (MeOD-d4): δ 9.03 (s, 1H), 7.71 (s, 1H), 7.10 (s, 1H), 6.77 (s, 1H), 4.73 (s, 2H), 4.00 (s, 3H), 3.95 (s, 31-1). MS (ES) (M+H) calc'd for C16H16N4O4S, 361; found 361.
Oxalyl chloride (8 μL, 0.092 mmol) was added to a solution of Example 49A (30 mg, 0.061 mmol) in dichloromethane (4 mL). Catalytic DMF was added, and the reaction stirred for 1 h. Methylamine (180 μL, 2M in THF, 0.366 mmol) was added, and the reaction stirred for 30 min. Organics were washed with brine, dried (MgSO4) and concentrated. Deprotection was carried out with hydrazine (0.2 mL) in methanol (3 mL), stirring for 1 h. Purification by Prep-HPLC gave 17.8 mg (60%) of the title compound (TFA salt) as a yellow solid. H1-NMR (MeOD-d4): δ 9.16 (s, 1H), 7.51 (s, 1H), 7.18 (s, 1H), 6.86 (s, 1H), 4.83 (s, 2H), 4.05 (s, 3H), 3.98 (s, 3H), 2.91 (s, 3H). MS (ES) (M+H) calc'd for C17H19N5O3S, 374; found 374.
The title compound was prepared in 48% yield using ethylamine according to the procedure for Example 50. H1-NMR (MeOD-d4): δ 9.06 (s, 1H), 7.50 (s, 1H), 7.15 (s, 1H), 6.85 (s, 1H), 4.82 (s, 2H), 4.05 (s, 3H), 3.98 (s, 3H), 3.37 (q, 2H, J=7.2 Hz), 1.20 (t, 3H, J=7.2 Hz). MS (ES) (M+H) calc'd for C18H21N5O3S, 388; found 388.
The title compound was prepared in 8% yield using ethanolamine according to the procedure for Example 50. H1-NMR (MeOD-d4): δ 9.04 (s, 1H), 7.51 (s, 1H), 7.14 (s, 1H), 6.83 (s, 1H), 4.82 (s, 2H), 4.05 (s, 3H), 3.98 (s, 3H), 3.68 (t, 21-1, J=5.6 Hz), 3.49 (t, 2H, J=5.6 Hz). MS (ES) [m+H] calc'd for C18H21N5O4S, 404; found 404.
The protease inhibitory activities of DPP-IV inhibitors can be readily determined by methods known to those of ordinary skill in the art since suitable in vitro assays for measuring protease activity and the inhibition thereof by test compounds are known. Examples of assays that may be used for measuring protease inhibitory activity and selectivity are set forth below.
DPP-IV Assay
Solutions of test compounds in varying concentrations (0.10 mM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 20 mM Tris, pH 7.4; 20 mM KCl; and 0.1 mg/mL BSA. Human DPP-IV (0.1 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4-trifluoromethylcoumarin (AP-AFC; 10 μM final concentration). The total volume of the reaction mixture was 10-1004 depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=400 nm; emission λ=505 nm) for 5-10 minutes or an end-point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
FAPα Assay
Solutions of test compounds in varying concentrations (≦10 mM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 20 mM Tris, pH 7.4; 20 mM KCl; and 0.1 mg/mL BSA. Human FAPα (2 nM final concentration) was added to the dilutions and pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with A-P-7-amido-4-trifluoromethylcoumarin (AP-AFC; 40 μM final concentration). The total volume of the reaction mixture was 10-100 μL depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=400 nm; emission λ=505 nm) for 5-10 minutes or an end-point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
PREP Assay
Solutions of test compounds in varying concentrations (≦10 mM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 20 mM Sodium Phosphate, pH 7.4; 0.5 mM EDTA; 0.5 mM DTT; and 0.1 mg/mL BSA. PREP (EC3.4.21.26 from Flavobacterium meningosepticum; 0.2 nM final concentration) was added to the dilutions. The PREP and compound were pre-incubated for 10 minutes at ambient temperature before the reaction was initiated with Z-G-P-AMC (10 μM final concentration). The total volume of the reaction mixture was 10-100 μL depending on assay formats used (384 or 96 well plates). The reaction was followed kinetically (excitation λ=375 nm; emission λ=460 nm) for 10 minutes or an end-point was measured after 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
Tryptase Assay
Solutions of test compounds in varying concentrations (≦10 mM final concentration) were prepared in Dimethyl Sulfoxide (DMSO) and then diluted into assay buffer comprising: 100 mM Hepes, pH 7.4; 0.01% Brij35; and 10% glycerol. Tryptase (rhLung beta; 0.1 nM final concentration) was added to the dilutions and pre-incubated with compound for 10 minutes at ambient temperature. The enzymatic reaction was initiated with 25 μM Z-lys-SBz1 and 400 μM DTNB. The total volume of the reaction mixture was 1004 in Costar A/2 96 well plates. The reaction was followed colorimetrically (λ=405 nm) for 10 minutes. Inhibition constants (IC50) were calculated from the enzyme progress curves using standard mathematical models.
Compounds of the invention were tested according to the above-described assays for protease inhibition and observed to exhibit selective DPP-IV inhibitory activity. For example, compounds of the invention were found to inhibit DPP-IV activity at concentrations that are at least 50 fold less than those concentrations required to produce an equiactive inhibition of protease activity for FAPα. The apparent inhibition constants (Ki) for compounds of the invention, against DPP-IV, were in the range from about 10−9M to about 10−5M.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compounds, compositions, kits, and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
This application claims the benefit of U.S. Provisional Application No. 60/552,657, filed Mar. 11, 2004, which is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2961377 | Shapiro et al. | Nov 1960 | A |
| 3960949 | Ahrens et al. | Jun 1976 | A |
| 4494978 | Chan | Jan 1985 | A |
| 4935493 | Bachovchin et al. | Jun 1990 | A |
| 4958026 | Schoellkopf et al. | Sep 1990 | A |
| 5268376 | Gester | Dec 1993 | A |
| 5342843 | Suzuki et al. | Aug 1994 | A |
| 5366862 | Venton et al. | Nov 1994 | A |
| 5387512 | Balani et al. | Feb 1995 | A |
| 5433955 | Bredehorst et al. | Jul 1995 | A |
| 5462928 | Bachovchin et al. | Oct 1995 | A |
| 5512549 | Chen et al. | Apr 1996 | A |
| 5543396 | Powers et al. | Aug 1996 | A |
| 5580979 | Bachovchin | Dec 1996 | A |
| 5589437 | Vichnevetskaia et al. | Dec 1996 | A |
| 5601986 | Takacs | Feb 1997 | A |
| 5614379 | MacKellar | Mar 1997 | A |
| 5624894 | Bodor | Apr 1997 | A |
| 5776902 | Bachovchin | Jul 1998 | A |
| 5798344 | Kuroki et al. | Aug 1998 | A |
| 5811278 | Okamura et al. | Sep 1998 | A |
| 5811281 | Quaroni et al. | Sep 1998 | A |
| 5814460 | Venton et al. | Sep 1998 | A |
| 5885997 | Lohray et al. | Mar 1999 | A |
| 5939560 | Jenkins et al. | Aug 1999 | A |
| 5965532 | Bachovchin | Oct 1999 | A |
| 5985884 | Lohray et al. | Nov 1999 | A |
| 6006753 | Efendic | Dec 1999 | A |
| 6011155 | Villhauer | Jan 2000 | A |
| 6090786 | Augustyns et al. | Jul 2000 | A |
| 6107317 | Villhauer | Aug 2000 | A |
| 6110949 | Villhauer | Aug 2000 | A |
| 6124305 | Villhauer | Sep 2000 | A |
| 6129911 | Faris | Oct 2000 | A |
| 6156739 | Griffin et al. | Dec 2000 | A |
| 6166063 | Villhauer | Dec 2000 | A |
| 6172081 | Damon | Jan 2001 | B1 |
| 6184020 | Blinkovsky et al. | Feb 2001 | B1 |
| 6201132 | Jenkins et al. | Mar 2001 | B1 |
| 6235493 | Bissell et al. | May 2001 | B1 |
| 6251391 | Wilkinson et al. | Jun 2001 | B1 |
| 6258597 | Bachovchin et al. | Jul 2001 | B1 |
| 6261794 | Chang | Jul 2001 | B1 |
| 6265551 | Duke-Cohan et al. | Jul 2001 | B1 |
| 6300314 | Wallner et al. | Oct 2001 | B1 |
| 6303661 | Demuth et al. | Oct 2001 | B1 |
| 6309868 | Monod et al. | Oct 2001 | B1 |
| 6310069 | Lohray et al. | Oct 2001 | B1 |
| 6319893 | Demuth et al. | Nov 2001 | B1 |
| 6325989 | Duke-Cohan et al. | Dec 2001 | B1 |
| 6335429 | Cai et al. | Jan 2002 | B1 |
| 6337069 | Grouzmann et al. | Jan 2002 | B1 |
| 6342611 | Weber et al. | Jan 2002 | B1 |
| 6355614 | Wallner | Mar 2002 | B1 |
| 6380398 | Kanstrup et al. | Apr 2002 | B2 |
| 6395767 | Robl et al. | May 2002 | B2 |
| 6432969 | Villhauer | Aug 2002 | B1 |
| 6458924 | Knudsen et al. | Oct 2002 | B2 |
| 6485955 | Huber et al. | Nov 2002 | B1 |
| 6495544 | Hansen, Jr. et al. | Dec 2002 | B2 |
| 6500804 | Demuth et al. | Dec 2002 | B2 |
| 6521644 | Broqua | Feb 2003 | B1 |
| 6528486 | Larsen et al. | Mar 2003 | B1 |
| 6545170 | Pitzele et al. | Apr 2003 | B2 |
| 6548481 | Demuth et al. | Apr 2003 | B1 |
| 6555519 | Washburn | Apr 2003 | B2 |
| 6555521 | Hermeling et al. | Apr 2003 | B2 |
| 6573096 | Chen | Jun 2003 | B1 |
| 6573287 | Sulsky et al. | Jun 2003 | B2 |
| 6583111 | DiMarchi et al. | Jun 2003 | B1 |
| 6586198 | Brown | Jul 2003 | B2 |
| 6608038 | Caplan et al. | Aug 2003 | B2 |
| 6613879 | Firestone | Sep 2003 | B1 |
| 6617340 | Villhauer | Sep 2003 | B1 |
| 6620821 | Robl | Sep 2003 | B2 |
| 6620910 | Calas et al. | Sep 2003 | B1 |
| 6627636 | Robl | Sep 2003 | B2 |
| 6645995 | Kanstrup et al. | Nov 2003 | B2 |
| 6660716 | Yakubu-Madus et al. | Dec 2003 | B1 |
| 6664092 | Blinkovsky | Dec 2003 | B1 |
| 6673815 | Devasthale et al. | Jan 2004 | B2 |
| 6673829 | Dorwald et al. | Jan 2004 | B2 |
| 6686337 | Connor | Feb 2004 | B2 |
| 6699871 | Edmondson et al. | Mar 2004 | B2 |
| 6703238 | Bachovchin et al. | Mar 2004 | B2 |
| 6706742 | De Nanteuil et al. | Mar 2004 | B2 |
| 6710040 | Hulin et al. | Mar 2004 | B1 |
| 6716843 | De Nanteuil et al. | Apr 2004 | B2 |
| 6727261 | Gobbi et al. | Apr 2004 | B2 |
| 6727271 | Cheng et al. | Apr 2004 | B2 |
| 6800650 | Boehringer et al. | Oct 2004 | B2 |
| 6803357 | Bachovchin et al. | Oct 2004 | B1 |
| 6825169 | Bachovchin et al. | Nov 2004 | B1 |
| 6844180 | Oi et al. | Jan 2005 | B2 |
| 6861440 | Boehringer et al. | Mar 2005 | B2 |
| 6864363 | Travis et al. | Mar 2005 | B2 |
| 6867205 | Boehringer et al. | Mar 2005 | B2 |
| 20010018210 | Bachovchin et al. | Aug 2001 | A1 |
| 20010020006 | Demuth et al. | Sep 2001 | A1 |
| 20010025023 | Carr | Sep 2001 | A1 |
| 20010031780 | Kanstrup et al. | Oct 2001 | A1 |
| 20010047078 | Chang | Nov 2001 | A1 |
| 20010051646 | Demuth et al. | Dec 2001 | A1 |
| 20020006899 | Pospisilik et al. | Jan 2002 | A1 |
| 20020019411 | Robl et al. | Feb 2002 | A1 |
| 20020037829 | Aronson et al. | Mar 2002 | A1 |
| 20020041871 | Brudnak | Apr 2002 | A1 |
| 20020049164 | Demuth et al. | Apr 2002 | A1 |
| 20020061839 | Scharpe et al. | May 2002 | A1 |
| 20020071838 | Demuth et al. | Jun 2002 | A1 |
| 20020077340 | Sulsky et al. | Jun 2002 | A1 |
| 20020082427 | Demuth et al. | Jun 2002 | A1 |
| 20020103384 | Kanstrup et al. | Aug 2002 | A1 |
| 20020110560 | Demuth et al. | Aug 2002 | A1 |
| 20020115843 | Oi et al. | Aug 2002 | A1 |
| 20020132979 | Chen | Sep 2002 | A1 |
| 20020147130 | Huber et al. | Oct 2002 | A1 |
| 20020147157 | Connor | Oct 2002 | A1 |
| 20020155565 | Garin-Chesa et al. | Oct 2002 | A1 |
| 20020161001 | Kanstrup et al. | Oct 2002 | A1 |
| 20020164759 | Travis et al. | Nov 2002 | A1 |
| 20020165164 | Demuth et al. | Nov 2002 | A1 |
| 20020169159 | Medina et al. | Nov 2002 | A1 |
| 20020183367 | Sulsky et al. | Dec 2002 | A1 |
| 20020193390 | Villhauer | Dec 2002 | A1 |
| 20020198205 | Himmelsbach et al. | Dec 2002 | A1 |
| 20020198242 | Demuth et al. | Dec 2002 | A1 |
| 20020198380 | Belzer et al. | Dec 2002 | A1 |
| 20030008905 | Demuth et al. | Jan 2003 | A1 |
| 20030027282 | Huber et al. | Feb 2003 | A1 |
| 20030045464 | Hermeling et al. | Mar 2003 | A1 |
| 20030055052 | Peters et al. | Mar 2003 | A1 |
| 20030060494 | Yasuda et al. | Mar 2003 | A1 |
| 20030069234 | Medina et al. | Apr 2003 | A1 |
| 20030087935 | Cheng et al. | May 2003 | A1 |
| 20030087950 | DeNanteuil et al. | May 2003 | A1 |
| 20030092630 | Demuth et al. | May 2003 | A2 |
| 20030092697 | Cheng et al. | May 2003 | A1 |
| 20030096857 | Evans et al. | May 2003 | A1 |
| 20030103968 | Amelsberg et al. | Jun 2003 | A1 |
| 20030105077 | Kanstrup et al. | Jun 2003 | A1 |
| 20030119736 | Demuth et al. | Jun 2003 | A1 |
| 20030119738 | Niestroj et al. | Jun 2003 | A1 |
| 20030119750 | Demuth et al. | Jun 2003 | A1 |
| 20030125304 | Demuth et al. | Jul 2003 | A1 |
| 20030130199 | von Hoersten et al. | Jul 2003 | A1 |
| 20030130281 | Boehringer et al. | Jul 2003 | A1 |
| 20030130306 | Devasthale et al. | Jul 2003 | A1 |
| 20030134802 | Demuth et al. | Jul 2003 | A1 |
| 20030135023 | Demuth et al. | Jul 2003 | A1 |
| 20030139429 | Cohen et al. | Jul 2003 | A1 |
| 20030139434 | Balkan et al. | Jul 2003 | A1 |
| 20030144206 | Knudsen et al. | Jul 2003 | A1 |
| 20030148961 | Heiser et al. | Aug 2003 | A1 |
| 20030149071 | Gobbi et al. | Aug 2003 | A1 |
| 20030153509 | Bachovchin et al. | Aug 2003 | A1 |
| 20030158114 | Wallner et al. | Aug 2003 | A1 |
| 20030162820 | Demuth et al. | Aug 2003 | A1 |
| 20030165818 | Edbrooke et al. | Sep 2003 | A1 |
| 20030166050 | Kapeller-Libermann | Sep 2003 | A1 |
| 20030166578 | Arch et al. | Sep 2003 | A1 |
| 20030166662 | Fryburg et al. | Sep 2003 | A1 |
| 20030166690 | Ebdrup et al. | Sep 2003 | A1 |
| 20030171358 | Jeppesen et al. | Sep 2003 | A1 |
| 20030171411 | Kodra et al. | Sep 2003 | A1 |
| 20030176357 | Pospisilik et al. | Sep 2003 | A1 |
| 20030180828 | Brown | Sep 2003 | A1 |
| 20030181497 | Chen et al. | Sep 2003 | A1 |
| 20030186963 | Dorwald et al. | Oct 2003 | A1 |
| 20030187254 | Perry et al. | Oct 2003 | A1 |
| 20030190670 | Bursavich et al. | Oct 2003 | A1 |
| 20030191112 | Dorwald et al. | Oct 2003 | A1 |
| 20030195188 | Boehringer et al. | Oct 2003 | A1 |
| 20030195190 | Peschke et al. | Oct 2003 | A1 |
| 20030199451 | Mogensen et al. | Oct 2003 | A1 |
| 20030199528 | Kanstrup et al. | Oct 2003 | A1 |
| 20030199563 | Robl et al. | Oct 2003 | A1 |
| 20030199672 | Knudsen et al. | Oct 2003 | A1 |
| 20030203946 | Behrens et al. | Oct 2003 | A1 |
| 20030206901 | Chen | Nov 2003 | A1 |
| 20030216382 | Boehringer et al. | Nov 2003 | A1 |
| 20030216450 | Evans et al. | Nov 2003 | A1 |
| 20030220345 | Hamby et al. | Nov 2003 | A1 |
| 20030225102 | Sankaranarayanan | Dec 2003 | A1 |
| 20030232761 | Hinke et al. | Dec 2003 | A1 |
| 20030236272 | Carr | Dec 2003 | A1 |
| 20040002495 | Sher et al. | Jan 2004 | A1 |
| 20040002609 | Hulin | Jan 2004 | A1 |
| 20040006062 | Smallheer et al. | Jan 2004 | A1 |
| 20040009972 | Ding et al. | Jan 2004 | A1 |
| 20040009998 | Dhar et al. | Jan 2004 | A1 |
| 20040034014 | Kanstrup et al. | Feb 2004 | A1 |
| 20040053369 | Abbott et al. | Mar 2004 | A1 |
| 20040054171 | Jensen et al. | Mar 2004 | A1 |
| 20040058876 | Hoffmann et al. | Mar 2004 | A1 |
| 20040063935 | Yasuda et al. | Apr 2004 | A1 |
| 20040072874 | Sato et al. | Apr 2004 | A1 |
| 20040072892 | Fukushima et al. | Apr 2004 | A1 |
| 20040077645 | Himmelsbach et al. | Apr 2004 | A1 |
| 20040082497 | Evans et al. | Apr 2004 | A1 |
| 20040082607 | Oi et al. | Apr 2004 | A1 |
| 20040087587 | Himmelsbach et al. | May 2004 | A1 |
| 20040092478 | Rothermel et al. | May 2004 | A1 |
| 20040097510 | Himmelsbach et al. | May 2004 | A1 |
| 20040106655 | Kitajima et al. | Jun 2004 | A1 |
| 20040106656 | Ashton et al. | Jun 2004 | A1 |
| 20040106802 | Sankaranarayanan | Jun 2004 | A1 |
| 20040110817 | Hulin | Jun 2004 | A1 |
| 20040115202 | Chen | Jun 2004 | A1 |
| 20040116328 | Yoshikawa et al. | Jun 2004 | A1 |
| 20040122228 | Maier et al. | Jun 2004 | A1 |
| 20040132639 | Ansorge et al. | Jul 2004 | A1 |
| 20040132713 | Hulin et al. | Jul 2004 | A1 |
| 20040132732 | Han et al. | Jul 2004 | A1 |
| 20040138148 | Fushimi et al. | Jul 2004 | A1 |
| 20040138214 | Himmelsbach et al. | Jul 2004 | A1 |
| 20040138215 | Eckhardt et al. | Jul 2004 | A1 |
| 20040147434 | Ansorge et al. | Jul 2004 | A1 |
| 20040152192 | Bachovchin et al. | Aug 2004 | A1 |
| 20040152745 | Jackson et al. | Aug 2004 | A1 |
| 20040166125 | Himmelsbach et al. | Aug 2004 | A1 |
| 20040167133 | Edmondson et al. | Aug 2004 | A1 |
| 20040167191 | Demuth et al. | Aug 2004 | A1 |
| 20040167341 | Haffner et al. | Aug 2004 | A1 |
| 20040171104 | Blinkovsky et al. | Sep 2004 | A1 |
| 20040171555 | Demuth et al. | Sep 2004 | A1 |
| 20040171848 | Haffner et al. | Sep 2004 | A1 |
| 20040176406 | Gobbi et al. | Sep 2004 | A1 |
| 20040176428 | Edmondson et al. | Sep 2004 | A1 |
| 20040180396 | Bergmann et al. | Sep 2004 | A1 |
| 20040180925 | Matsuno et al. | Sep 2004 | A1 |
| 20040186153 | Yasuda et al. | Sep 2004 | A1 |
| 20040191826 | Abbott et al. | Sep 2004 | A1 |
| 20040191844 | Weber et al. | Sep 2004 | A1 |
| 20040198786 | Gretzke et al. | Oct 2004 | A1 |
| 20040209891 | Broqua et al. | Oct 2004 | A1 |
| 20040229820 | Bachovchin et al. | Nov 2004 | A1 |
| 20040229848 | Demuth et al. | Nov 2004 | A1 |
| 20040236102 | Brockunier et al. | Nov 2004 | A1 |
| 20040242566 | Feng et al. | Dec 2004 | A1 |
| 20040242568 | Feng et al. | Dec 2004 | A1 |
| 20040242636 | Haffner et al. | Dec 2004 | A1 |
| 20040242898 | Hulin et al. | Dec 2004 | A1 |
| 20040254167 | Biftu et al. | Dec 2004 | A1 |
| 20040254226 | Feng et al. | Dec 2004 | A1 |
| 20040259843 | Madar et al. | Dec 2004 | A1 |
| 20040259870 | Feng et al. | Dec 2004 | A1 |
| 20040259883 | Sakashita et al. | Dec 2004 | A1 |
| 20040259902 | Boehringer et al. | Dec 2004 | A1 |
| 20040259903 | Boehringer et al. | Dec 2004 | A1 |
| 20040259919 | Magnin et al. | Dec 2004 | A1 |
| 20050014699 | Ansorge et al. | Jan 2005 | A1 |
| 20050014732 | Gulve et al. | Jan 2005 | A1 |
| 20050014946 | Demuth et al. | Jan 2005 | A1 |
| 20050020574 | Hauel et al. | Jan 2005 | A1 |
| 20050026921 | Eckhardt et al. | Feb 2005 | A1 |
| 20050032804 | Cypes et al. | Feb 2005 | A1 |
| 20050038020 | Hamann et al. | Feb 2005 | A1 |
| 20050043292 | Parker et al. | Feb 2005 | A1 |
| 20050043299 | Evans et al. | Feb 2005 | A1 |
| 20050058635 | Demuth et al. | Mar 2005 | A1 |
| Number | Date | Country |
|---|---|---|
| 0505893 | Sep 1992 | EP |
| 0547514 | Jun 1993 | EP |
| 0574846 | Dec 1993 | EP |
| 0657452 | Jun 1995 | EP |
| 0702013 | Mar 1996 | EP |
| 1258480 | Nov 2002 | EP |
| WO 8910701 | Nov 1989 | WO |
| WO 9111457 | Aug 1991 | WO |
| WO 9112001 | Aug 1991 | WO |
| WO 9308259 (A2) | Apr 1993 | WO |
| WO 9308259 (A3) | Apr 1993 | WO |
| WO 9324634 | Dec 1993 | WO |
| WO 9403055 | Feb 1994 | WO |
| WO 9515309 | Jun 1995 | WO |
| WO 9529691 | Nov 1995 | WO |
| WO 9602667 | Feb 1996 | WO |
| WO 9638550 | Dec 1996 | WO |
| WO 9740832 | Nov 1997 | WO |
| WO 9818763 | May 1998 | WO |
| WO 9819998 | May 1998 | WO |
| WO 9850046 | Nov 1998 | WO |
| WO 9851803 | Nov 1998 | WO |
| WO 9902705 | Jan 1999 | WO |
| WO 9916864 | Apr 1999 | WO |
| WO 9917799 | Apr 1999 | WO |
| WO 9918856 | Apr 1999 | WO |
| WO 9928474 | Jun 1999 | WO |
| WO 9938501 | Aug 1999 | WO |
| WO 9946272 | Sep 1999 | WO |
| WO 9947152 | Sep 1999 | WO |
| WO 9961431 | Dec 1999 | WO |
| WO 9962914 | Dec 1999 | WO |
| WO 9967278 | Dec 1999 | WO |
| WO 9967279 | Dec 1999 | WO |
| WO 0009506 | Feb 2000 | WO |
| WO 0010549 | Mar 2000 | WO |
| WO 0020416 | Apr 2000 | WO |
| WO 0034241 | Jun 2000 | WO |
| WO 0040583 | Jul 2000 | WO |
| WO 0043366 | Jul 2000 | WO |
| WO 0053171 | Sep 2000 | WO |
| WO 0056296 | Sep 2000 | WO |
| WO 0056297 | Sep 2000 | WO |
| WO 0076986 | Dec 2000 | WO |
| WO 0114318 | Mar 2001 | WO |
| WO 0116301 | Mar 2001 | WO |
| WO 0119866 | Mar 2001 | WO |
| WO 0134594 | May 2001 | WO |
| WO 0140180 | Jun 2001 | WO |
| WO 0152825 | Jul 2001 | WO |
| WO 0155105 | Aug 2001 | WO |
| WO 0162266 | Aug 2001 | WO |
| WO 0168603 | Sep 2001 | WO |
| WO 0172290 | Oct 2001 | WO |
| WO 0174299 | Oct 2001 | WO |
| WO 0179206 | Oct 2001 | WO |
| WO 0181304 | Nov 2001 | WO |
| WO 0181337 | Nov 2001 | WO |
| WO 0189569 | Nov 2001 | WO |
| WO 0194597 | Dec 2001 | WO |
| WO 0196295 | Dec 2001 | WO |
| WO 0197808 | Dec 2001 | WO |
| WO 0202560 | Jan 2002 | WO |
| WO 0204610 | Jan 2002 | WO |
| WO 0214271 | Feb 2002 | WO |
| WO 0220804 | Mar 2002 | WO |
| WO 0228742 | Apr 2002 | WO |
| WO 0230890 | Apr 2002 | WO |
| WO 0231134 | Apr 2002 | WO |
| WO 0234242 | May 2002 | WO |
| WO 0234243 | May 2002 | WO |
| WO 0234900 | May 2002 | WO |
| WO 0238541 | May 2002 | WO |
| WO 02051836 | Jul 2002 | WO |
| WO 02053170 | Jul 2002 | WO |
| WO 02059301 | Aug 2002 | WO |
| WO 02059343 | Aug 2002 | WO |
| WO 02062764 | Aug 2002 | WO |
| WO 02066627 | Aug 2002 | WO |
| WO 02068420 | Sep 2002 | WO |
| WO 02076450 | Oct 2002 | WO |
| WO 02083109 | Oct 2002 | WO |
| WO 02083128 | Oct 2002 | WO |
| WO 02092127 | Nov 2002 | WO |
| WO 02094178 | Nov 2002 | WO |
| WO 02096357 | Dec 2002 | WO |
| WO 03000180 | Jan 2003 | WO |
| WO 03000181 | Jan 2003 | WO |
| WO 03000250 | Jan 2003 | WO |
| WO 03002530 | Jan 2003 | WO |
| WO 03002531 | Jan 2003 | WO |
| WO 03002553 | Jan 2003 | WO |
| WO 03002593 | Jan 2003 | WO |
| WO 03002595 | Jan 2003 | WO |
| WO 03002596 | Jan 2003 | WO |
| WO 03004496 | Jan 2003 | WO |
| WO 03004498 | Jan 2003 | WO |
| WO 03007888 | Jan 2003 | WO |
| WO 03010197 | Feb 2003 | WO |
| WO 03010314 | Feb 2003 | WO |
| WO 03011807 | Feb 2003 | WO |
| WO 03011814 | Feb 2003 | WO |
| WO 03011834 | Feb 2003 | WO |
| WO 03011892 | Feb 2003 | WO |
| WO 03014318 | Feb 2003 | WO |
| WO 03015775 | Feb 2003 | WO |
| WO 03016335 | Feb 2003 | WO |
| WO 03017936 | Mar 2003 | WO |
| WO 03022871 | Mar 2003 | WO |
| WO 03024942 | Mar 2003 | WO |
| WO 03024965 | Mar 2003 | WO |
| WO 03026652 | Apr 2003 | WO |
| WO 03030946 | Apr 2003 | WO |
| WO 03033524 | Apr 2003 | WO |
| WO 03033671 | Apr 2003 | WO |
| WO 03035057 | May 2003 | WO |
| WO 03035067 | May 2003 | WO |
| WO 03037327 | May 2003 | WO |
| WO 03038123 | May 2003 | WO |
| WO 03040114 | May 2003 | WO |
| WO 03040174 | May 2003 | WO |
| WO 03045228 | Jun 2003 | WO |
| WO 03048081 | Jun 2003 | WO |
| WO 03048158 | Jun 2003 | WO |
| WO 03051848 | Jun 2003 | WO |
| WO 031045977 | Jun 2003 | WO |
| WO 03053330 | Jul 2003 | WO |
| WO 03055881 | Jul 2003 | WO |
| WO 03057144 | Jul 2003 | WO |
| WO 03057200 | Jul 2003 | WO |
| WO 03057666 | Jul 2003 | WO |
| WO 03063903 | Aug 2003 | WO |
| WO 03065983 | Aug 2003 | WO |
| WO 03068748 | Aug 2003 | WO |
| WO 03068757 | Aug 2003 | WO |
| WO 03072197 | Sep 2003 | WO |
| WO 03072556 | Sep 2003 | WO |
| WO 03074500 | Sep 2003 | WO |
| WO 03076418 | Sep 2003 | WO |
| WO 03077935 | Sep 2003 | WO |
| WO 03080070 | Oct 2003 | WO |
| WO 03080633 | Oct 2003 | WO |
| WO 03082817 | Oct 2003 | WO |
| WO 03082859 | Oct 2003 | WO |
| WO 03082898 | Oct 2003 | WO |
| WO 03084940 | Oct 2003 | WO |
| WO 03092605 | Nov 2003 | WO |
| WO 03099279 | Dec 2003 | WO |
| WO 03099818 | Dec 2003 | WO |
| WO 03101449 | Dec 2003 | WO |
| WO 03101958 | Dec 2003 | WO |
| WO 03104207 | Dec 2003 | WO |
| WO 03104208 | Dec 2003 | WO |
| WO 03104229 | Dec 2003 | WO |
| WO 03106456 | Dec 2003 | WO |
| WO 2004002535 | Jan 2004 | WO |
| WO 2004002986 | Jan 2004 | WO |
| WO 2004004655 | Jan 2004 | WO |
| WO 2004004661 | Jan 2004 | WO |
| WO 2004004665 | Jan 2004 | WO |
| WO 2004007446 | Jan 2004 | WO |
| WO 2004007468 | Jan 2004 | WO |
| WO 2004011640 | Feb 2004 | WO |
| WO 2004014860 | Feb 2004 | WO |
| WO 2004017989 | Mar 2004 | WO |
| WO2004018467 | Mar 2004 | WO |
| WO2004018467 | Mar 2004 | WO |
| WO 2004018468 | Mar 2004 | WO |
| WO 2004018469 | Mar 2004 | WO |
| WO 2004020407 | Mar 2004 | WO |
| WO 2004024184 | Mar 2004 | WO |
| WO 2004026822 | Apr 2004 | WO |
| WO 2004028524 | Apr 2004 | WO |
| WO 2004031175 | Apr 2004 | WO |
| WO 2004031374 | Apr 2004 | WO |
| WO 2004032836 | Apr 2004 | WO |
| WO 2004032861 | Apr 2004 | WO |
| WO 2004033455 | Apr 2004 | WO |
| WO 2004037169 | May 2004 | WO |
| WO 2004037176 | May 2004 | WO |
| WO 2004037181 | May 2004 | WO |
| WO 2004041795 | May 2004 | WO |
| WO 2004043940 | May 2004 | WO |
| WO 2004046106 | Jun 2004 | WO |
| WO 2004048352 | Jun 2004 | WO |
| WO 2004050022 | Jun 2004 | WO |
| WO 2004050656 | Jun 2004 | WO |
| WO2004050658 | Jun 2004 | WO |
| WO 2004052850 | Jun 2004 | WO |
| WO 2004058266 | Jul 2004 | WO |
| WO 2004064778 | Aug 2004 | WO |
| WO 2004067509 | Aug 2004 | WO |
| WO 2004069162 | Aug 2004 | WO |
| WO 2004071454 | Aug 2004 | WO |
| WO 2004075815 | Sep 2004 | WO |
| WO 2004075891 | Sep 2004 | WO |
| WO 2004076401 | Sep 2004 | WO |
| WO 2004076433 | Sep 2004 | WO |
| WO 2004076434 | Sep 2004 | WO |
| WO 2004078777 | Sep 2004 | WO |
| WO 2004080958 | Sep 2004 | WO |
| WO 2004082599 | Sep 2004 | WO |
| WO 2004083212 | Sep 2004 | WO |
| WO 2004085661 | Oct 2004 | WO |
| WO 2004087053 | Oct 2004 | WO |
| WO 2004087650 | Oct 2004 | WO |
| WO 2004087880 | Oct 2004 | WO |
| WO 2004089362 | Oct 2004 | WO |
| WO 2004096806 | Nov 2004 | WO |
| WO 2004098625 | Nov 2004 | WO |
| WO 2004099134 | Nov 2004 | WO |
| WO 2004099185 | Nov 2004 | WO |
| WO 2004101514 | Nov 2004 | WO |
| WO 2004103276 | Dec 2004 | WO |
| WO 2004103993 | Dec 2004 | WO |
| WO 2004104215 | Dec 2004 | WO |
| WO 2004110436 | Dec 2004 | WO |
| WO 2004111041 | Dec 2004 | WO |
| WO 2004111051 | Dec 2004 | WO |
| WO 2004112701 | Dec 2004 | WO |
| WO 2005000846 | Jan 2005 | WO |
| WO 2005000848 | Jan 2005 | WO |
| WO 2005003135 | Jan 2005 | WO |
| WO 2005004906 | Jan 2005 | WO |
| WO 2005011581 | Feb 2005 | WO |
| WO 2005012249 | Feb 2005 | WO |
| WO 2005016911 | Feb 2005 | WO |
| WO 2005019168 | Mar 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 60552657 | Mar 2004 | US |
